Clinical trial NCT03708744
Conditions: Migraine
Keywords: Healthy Volunteer Pharmacokinetics
Sponsor: Zosano Pharma Corporation
Start date: 2018-11-01; Completion date: 2018-11-20
Enrollment: 24 participants; Allocation: RANDOMIZED; Intervention model: CROSSOVER

Brief summary:
This is a single-center, open-label, randomized, four-way crossover study. Each subject will receive each of the four study treatments once, followed by in-clinic monitoring and extensive blood sample collection for pharmacokinetic analysis.

Dosing will occur approximately 48 hours apart, until completion of dosing in randomized order per the treatment sequence tables. Plasma samples from the dosing days will be sent to the analytical laboratory for analysis and tolerability for each of the dose levels will be summarized.

After completion of the four dosing days, subjects will be assessed one final time and dismissed from the study.

Detailed description:
This is a single-center, open-label, randomized, four-way crossover study to compare the pharmacokinetics, safety and tolerability of:

M207 3.8 mg administered to the upper arm to M207 3.8 mg administered to the thigh, particularly with respect to skin irritation (erythema, edema, bruising, bleeding):

M207 3.8 mg worn for 30 minutes on the upper arm to M207 3.8 mg worn for 1 hour on the upper arm; and M207 3.8 mg to intranasal zolmitriptan 2.5 mg.

Each subject will receive each of the four study treatments once, followed by in-clinic monitoring and extensive blood sample collection for pharmacokinetic analysis.

M207 application sites will be observed for erythema, edema, bruising, and bleeding at various timepoints throughout the study.

Dosing will occur approximately 48 hours apart, until completion of dosing in randomized order per the treatment sequence tables. Plasma samples from the dosing days will be sent to the analytical laboratory for analysis and tolerability for each of the dose levels will be summarized.

After completion of the four dosing days, subjects will be assessed one final time and dismissed from the study.

Arms: arm 1: Treatment A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application) arm 2: Treatment B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application) arm 3: Treatment C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application) arm 4: Treatment D: Intranasal zolmitriptan 2.5 mg
Interventions: intervention 1: A: M207 3.8mg, 30 min, upper arm intervention 2: B: M207 3.8 mg, 30 min, thigh intervention 3: C: M207 3.8 mg, 1 hr, upper arm intervention 4: D:zolmitriptan nasal spray
Intervention descriptions: intervention 1: A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application) intervention 2: B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application) intervention 3: C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application) intervention 4: D: 2.5 mg/0.1 mL intranasal zolmitriptan

Protocol documents:
Prot_000.pdf: 
 
 
C O N F I D E N T I A L 
Zosano Pharma  34790 Ardentech Court  Fremont, CA 94555 
 
CLINICAL PROTOCOL 
 
STUDY TITLE: 
A randomized open-label four-way crossover study to compare the 
pharmacokinetics, safety, and tolerability of M207 3.8 mg 
(administered as two 1.9 mg patches) at two different application 
locations (upper arm and thigh) for 30 minutes with intranasal 
zolmitriptan 2.5 mg and 1 hour wear time (upper arm) in healthy 
volunteers 
PROTOCOL NUMBER:  
CP-2018-002 
PROTOCOL VERSION: 
1.0  
PROTOCOL DATE:  
12 September 2018 
STUDY DRUG:  
 
M207 Intracutaneous Microneedle Patch System 
SPONSOR:  
Zosano Pharma Corporation 
34790 Ardentech Court 
Fremont, CA 94555  
United States 
SPONSOR CONTACT:  
Peter Schmidt, MD, MSc 
34790 Ardentech Court 
Fremont, CA 94555 
United States 
 
 
 
This document is a confidential communication of Zosano Pharma. The recipient agrees that no 
information contained herein will be published or disclosed without prior written approval of 
Zosano Pharma, except that this document may be disclosed to appropriate institutional review 
boards or duly authorized representatives of the US Food and Drug Administration (FDA) or 
other regulatory agencies under the condition that they are asked to maintain confidentiality. 


ZOSANO 
PI-It\RlvtA 
Protocol CP-2018-002 
Clinical Protocol 
SPONSOR APPROVAL PAGE 
Stndy Title: A randomized open-label four-way crossover study to compare the 
pharmacokinetics, safety, and tolerability ofM207 3.8 mg (administered as two 1.9 mg patches) 
at two different application locations (upper arm and thigh) for 30 minutes with intranasal 
zolmitriptan 2.5 mg and 1 hour wear time (upper arm) in healthy volunteers 
Protocol Version: 1.0 
Version Date: 12 September 2018 
Protocol approved by: 
Hayley Lewis 
Senior Vice President, Operntions Regnlatory 
Date 
Donald Kellerman 
Date 
Peter Schmidt, MD 
·cal Affairs and Medical Monitor 
Date 
CONFIDENTIAL 
Zosano Pharma • 34790 Arden tech Court • Fremont, CA 94555 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 2 of 69 
 
PROTOCOL SIGNATURE PAGE - PRINCIPAL INVESTIGATOR 
 
Protocol Number:  CP-2018-002 
 
Study Title: 
A randomized open-label four-way crossover study to compare the 
pharmacokinetics, safety, and tolerability of M207 3.8 mg (administered 
as two 1.9 mg patches) at two different application locations (upper arm 
and thigh) for 30 minutes with intranasal zolmitriptan 2.5 mg and 1 hour 
wear time (upper arm) in healthy volunteers 
Protocol Date:  
12 September 2018 
I have received and read the protocol dated 12 September 2018. I agree to undertake the protocol 
as defined therein. I am aware that my adherence to the above protocol is mandatory and that any 
changes in the protocol or informed consent form must first be approved by Zosano Pharma and 
the Institutional Review Board/Independent Ethics Committee, except those changes necessary 
to eliminate apparent immediate hazards to subjects. Failure to adhere to these stipulations may 
constitute a breach of ICH-R Guidelines and United States (U.S.) Federal Regulations and may 
result in termination of the study. 
 
Principal Investigator: 
 
 
 
 
 
 
 
 
Signature 
 
Date 
 
 
 
 
 
 
 
 
Printed Name 
 
 
 
 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 3 of 69 
 
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS 
Abbreviation 
Definition 
AE 
Adverse event 
ALT 
Alanine aminotransferase 
AP 
Alkaline phosphatase 
AST 
Aspartate aminotransferase 
AUC 
Area under the curve 
AUC30min 
Area under the curve from minute 0 to minute 30 
AUCt 
Area under the curve from 0 hours to the last measureable 
concentration 
AUCinf 
Area under the curve extrapolated to infinity 
BMI 
Body Mass Index 
BP 
Blood pressure 
BSAP 
Bone specific alkaline phosphate 
C 
Celsius 
CBC 
Complete blood count 
Ct 
Concentration at time t 
CFR 
Code of Federal Regulations 
CM 
Concomitant medication 
cm2 
Centimeter squared 
Cmax  
Maximum observed plasma concentrations 
CPK 
Creatinine phosphokinase 
CRF 
Case report form 
dL 
Deciliter 
ECG 
Electrocardiogram 
EDTA 
Ethylenediaminetetraacetic acid 
F 
Fahrenheit 
GCP 
Good Clinical Practice 
GGT 
gamma glutamyl transpeptidase 
H 
Hour 
HCl 
Hydrochloride 
HRT 
Hormone replacement therapy 
ICF 
Informed consent form 
ICH 
International Conference on Harmonisation 
IEC 
Independent Ethics Committee 
IM 
Intramuscular 
IRB 
Institutional Review Board 
IV 
Intravenous 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 4 of 69 
 
Abbreviation 
Definition 
J 
Joules 
k 
Apparent elimination rate constant 
kg 
Kilogram 
KIU 
Kilo international units 
µg 
Microgram 
L 
Liter 
LDH 
Lactate dehydrogenase 
µm 
Micrometer 
M207 
Intracutaneous Microneedle System (M207) 
mL 
Milliliters 
mmol 
millimole(s) 
NSAID 
Nonsteroidal anti-inflammatory drug 
PD 
Pharmacodynamics 
PE 
Physical examination 
PK 
Pharmacokinetics 
PPI 
Proton pump inhibitors 
PRSPB 
Bruising 
PTH 
Parathyroid hormone  
SAE 
Serious adverse event 
SC 
Subcutaneous 
SD 
Standard deviation 
t½ 
Apparent half life 
TEAE 
Treatment-emergent adverse event 
Tmax 
Time to maximum concentration 
ZP 
Zosano Pharma 
M207 
Zosano intracutaneous microneedle system containing zolmitriptan 
 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 5 of 69 
 
TABLE OF CONTENTS 
PROTOCOL SIGNATURE PAGE - PRINCIPAL INVESTIGATOR ................................... 2 
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS .............................................. 3 
TABLE OF CONTENTS ............................................................................................................. 5 
PROTOCOL SYNOPSIS ............................................................................................................. 9 
1 
INTRODUCTION ......................................................................................... 14 
1.1 
Background ..................................................................................................................... 14 
1.2 
Investigational Products .................................................................................................. 14 
1.2.1 
M207 Intracutaneous Microneedle System ............................................................. 14 
1.2.2 
Zolmitriptan Nasal Spray ........................................................................................ 14 
2 
STUDY OBJECTIVES ................................................................................. 15 
3 
ETHICAL CONSIDERATIONS ................................................................. 16 
3.1 
Institutional Review ........................................................................................................ 16 
3.2 
Informed Consent ............................................................................................................ 16 
4 
INVESTIGATIONAL PLAN ....................................................................... 17 
4.1 
Overall Study Design ...................................................................................................... 17 
4.2 
Endpoints ......................................................................................................................... 17 
4.3 
Safety Considerations ...................................................................................................... 18 
4.4 
Study Population ............................................................................................................. 18 
4.4.1 
Inclusion Criteria: .................................................................................................... 18 
4.4.2 
Exclusion Criteria: ................................................................................................... 19 
4.5 
Early Termination ........................................................................................................... 20 
5 
STUDY TREATMENTS ............................................................................... 21 
5.1 
Study Drug Treatments ................................................................................................... 21 
5.2 
Study Treatment Assignment and Schedule.................................................................... 21 
5.3 
Study Treatment Accountability Procedures................................................................... 21 
5.4 
Prior and Concomitant Medications Allowed and prohibited During the Study ............ 22 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 6 of 69 
 
6 
STUDY VISIT SCHEDULE AND ASSESSMENTS ................................. 23 
6.1 
Screening ......................................................................................................................... 23 
6.1.1 
Screening Visit (Day -30 to -1) ............................................................................... 23 
6.2 
Admission/baseline (Day Before Each Dose) ................................................................. 24 
6.3 
Study Dosing Days .......................................................................................................... 25 
6.3.1 
Dosing Visit (all Periods) – All Treatments ............................................................ 25 
6.3.1.1 
Pre-Dose - Before treatment Administration on the Day of Dosing ................ 25 
6.3.1.2 
Treatment Administration (t = 0)...................................................................... 26 
6.3.1.3 
2 Minutes after Treatment Administration ....................................................... 26 
6.3.1.4 
5 Minutes after Treatment Administration ....................................................... 26 
6.3.1.5 
10 Minutes after Treatment Administration ..................................................... 26 
6.3.1.6 
15 Minutes after Treatment Administration ..................................................... 26 
6.3.1.7 
20 Minutes after Treatment Administration ..................................................... 26 
6.3.1.8 
30 Minutes after Treatment Administration ..................................................... 26 
6.3.1.9 
45 Minutes after Treatment Administration ..................................................... 27 
6.3.1.10 
60 Minutes after Treatment Administration ..................................................... 27 
6.3.1.11 
90 Minutes after Treatment Administration ..................................................... 27 
6.3.1.12 
Two Hours after Treatment Administration ..................................................... 27 
6.3.1.13 
Four Hours after Treatment Administration ..................................................... 27 
6.3.1.14 
Eight Hours after Treatment Administration .................................................... 27 
6.3.1.15 
Twelve Hours after Treatment Administration ................................................ 28 
6.3.1.16 
Twenty Four Hours after Treatment Administration ........................................ 28 
6.3.1.17 
Zolmitriptan PK Sample Handling ................................................................... 28 
6.4 
End of Study Visit/or Early Termination ........................................................................ 29 
6.5 
Post Study Phone Call - Follow-up on Adverse Events .................................................. 29 
6.6 
Early Termination ........................................................................................................... 29 
7 
STUDY PROCEDURES ............................................................................... 30 
7.1 
General Confinement Restrictions .................................................................................. 30 
7.2 
Collection, Processing and Assay of Samples ................................................................ 30 
7.3 
Assessment Details .......................................................................................................... 31 
7.3.1 
Clinical Laboratory Tests ........................................................................................ 31 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 7 of 69 
 
7.3.2 
Vital Signs ............................................................................................................... 31 
7.3.3 
Electrocardiograms .................................................................................................. 31 
7.3.4 
Investigator Visual Skin Assessments of the Application Sites .............................. 32 
7.3.4.1 
Erythema ........................................................................................................... 32 
7.3.4.2 
Edema ............................................................................................................... 32 
7.3.4.3 
Bruising ............................................................................................................ 32 
7.3.4.4 
Bleeding ............................................................................................................ 32 
7.3.5 
Residual Drug on Used M207 Patches .................................................................... 33 
7.3.6 
Residual Drug on Skin after M207 Patch Removal ................................................ 33 
7.3.7 
Patch Adhesion Assessment .................................................................................... 33 
7.3.8 
Recording Adverse Events ...................................................................................... 33 
8 
ADVERSE EVENTS ..................................................................................... 34 
8.1 
Adverse Event Definitions .............................................................................................. 34 
8.2 
Documentation and Reporting of Adverse Events By the Investigator .......................... 35 
8.2.1 
Duration ................................................................................................................... 35 
8.2.2 
Severity Ratings ...................................................................................................... 36 
8.2.3 
Relationship to Study Drug ..................................................................................... 36 
8.3 
Serious Adverse Event Definitions ................................................................................. 37 
8.4 
Reporting Requirements For Serious Adverse Events .................................................... 38 
8.4.1 
Sponsor SAE Contact Information .......................................................................... 38 
8.4.2 
Follow up of Adverse Events .................................................................................. 39 
9 
DATA MANAGEMENT ............................................................................... 40 
9.1 
Data Collection ................................................................................................................ 40 
9.2 
Database Management and Quality Control ................................................................... 40 
10 
STATISTICAL METHODS AND DATA ANALYSIS .............................. 41 
10.1 Sample Size Considerations ............................................................................................ 41 
10.2 Demographics and Baseline Characteristics ................................................................... 41 
10.3 Analysis Population and Handling of Drop-Outs ........................................................... 41 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 8 of 69 
 
10.4 Zolmitriptan Pharmacokinetics ....................................................................................... 41 
10.5 Analyses of Safety Data .................................................................................................. 42 
10.6 Analyses of Adhesion...................................................................................................... 42 
10.7 Analyses of Residual Drug .............................................................................................. 42 
11 
ADMINISTRATIVE PROCEDURES ......................................................... 43 
11.1 Changes to the Protocol................................................................................................... 43 
11.2 Investigator Reporting Responsibilities to the Independent Ethics Committee and Other 
Agencies 43 
11.3 Withdrawal and Study Termination ................................................................................ 43 
11.4 Monitoring ....................................................................................................................... 43 
11.5 Retention of Documents .................................................................................................. 44 
11.6 Publicaton Policy............................................................................................................. 44 
11.7 Auditing Procedures ........................................................................................................ 44 
12 
REFERENCES .............................................................................................. 45 
13 
SCHEDULE OF ASSESSMENTS ............................................................... 46 
APPENDIX 1: 
M207 PATCH ADMINISTRATION ............................................................ 48 
APPENDIX 2: 
ZOLMITRIPTAN PK SAMPLE HANDLING .......................................... 57 
APPENDIX 3: 
HANDLING AND PROCESSING OF USED PATCHES AND SKIN 
SWABS........................................................................................................... 58 
APPENDIX 4: 
SHIPPING PROCEDURES FOR UNUSED PATCHES AND NEW 
APPLICATORS ............................................................................................ 63 
APPENDIX 5: 
DECLARATION OF HELSINKI ................................................................ 65 
 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 9 of 69 
 
PROTOCOL SYNOPSIS 
TITLE 
A randomized open-label four-way crossover study to compare the 
pharmacokinetics, safety, and tolerability of M207 3.8 mg 
(administered as two 1.9 mg patches) at two different application 
locations (upper arm and thigh) for 30 minutes with intranasal 
zolmitriptan 2.5 mg and 1 hour wear time (upper arm) in healthy 
volunteers 
SPONSOR  
Zosano Pharma 
CLINICAL PHASE  
Phase 1 – Single Center 
INDICATION  
Acute Treatment of Migraine 
OBJECTIVES  
1. To compare the pharmacokinetics, safety and tolerability of 
M207 3.8 mg administered to either the upper arm or thigh, 
particularly with respect to skin irritation (erythema, edema,  
bruising, bleeding) 
2. To compare the  pharmacokinetics, safety and tolerability of 
M207 3.8 mg worn for either 30 minutes or 1 hour on the 
upper arm   
3. To compare the  pharmacokinetics, safety and tolerability of 
M207 3.8 mg to intranasal zolmitriptan 2.5 mg 
TREATMENTS 
• Treatment A: M207 3.8 mg administered as two 1.9 mg 
patches, 30 min wear time (upper arm application) 
• Treatment B: M207 3.8 mg administered as two 1.9 mg 
patches, 30 min wear time (thigh application) 
• Treatment C:  M207 3.8 mg administered as two 1.9 mg 
patches, 1 hour wear time (upper arm application) 
• Treatment D: Intranasal zolmitriptan 2.5mg 
BLINDING  
Open-label 
RANDOMIZATION  
Randomized to the sequence of treatments 
STUDY POPULATION  Healthy volunteers (females and males) 
NUMBER OF  
SUBJECTS  
24 (12 females; 12 males) 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 10 of 69 
 
ELIGIBILITY  
Inclusion Criteria 
1. Women or men 18 to 50 years of age 
2. Good general health with no clinically significant 
abnormalities as determined by medical history, physical 
examination, CBC, blood chemistry, urinalysis, and ECG.  
3. Negative urine drug and alcohol screens and negative serum 
pregnancy tests (for female subjects) at screening  
4. Consent of female subjects to use a medically effective 
method of contraception throughout the entire study period 
and for 30 days after the subject completes the study.  
Medically effective methods of contraception that may be 
used by the subject include abstinence, use of diaphragm 
and spermicide, intrauterine device (IUD), condom and 
vaginal spermicide, hormonal contraceptives (subjects must 
be stable on hormonal contraceptives for at least the prior 
3 months), surgical sterilization, and post-menopausal 
(≥ 2 years of amenorrhea).   
5. Ability to read, understand, and provide written informed 
consent that they understand the purpose of the study and 
procedures required for the study before enrolling in the 
study, and willingness to comply with all study procedures 
and restrictions. 
Exclusion Criteria 
1. Evidence of significant history of hepatic, reproductive, 
gastrointestinal, renal, bleeding, or hematological disorders 
including coagulation, pulmonary, neurological, respiratory, 
endocrine, or cardiovascular system abnormalities 
(especially hypertension, peripheral vascular disease, 
coronary artery disease, transient ischemic attacks, or 
cardiac rhythm abnormalities), psychiatric disorders, acute 
infection, or other conditions that would interfere with 
study participation or with the absorption, distribution, 
metabolism, or excretion of drugs. 
2. Presence of two or more risk factors for cardiovascular 
disease (family history of premature heart disease, 
hyperlipidemia, or hypertension) 
3. Any contraindication to zolmitriptan administration 
including: 
• History of coronary artery disease or coronary 
vasospasm 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 11 of 69 
 
• Symptomatic Wolf-Parkinson-White syndrome or other 
cardiac accessory conduction pathway disorders 
• History of stroke, transient ischemic attack, or 
hemiplegic or basilar migraine 
• Peripheral Vascular Disease 
• Ischemic bowel disease 
• Uncontrolled hypertension 
• Any history of hepatic impairment  
4. History of contact dermatitis or known dermatological 
disorders that would interfere with the study procedures or 
assessments  
5. Planned participation in activities which cause 
inflammation, irritation, sunburn, lesions, or tattoos at the 
intended application sites from 2 weeks prior to screening 
through their last day of study participation 
6. Use of any prescription anticoagulant within 1 month prior 
to the first dose  
7. Use of prescription and over the counter medications other 
than the following: 
• Hormone Replacement Therapy (HRT) 
• Birth control pills, patches, injections, or implants (all 
hormonal contraceptives) are allowed provided the dose 
has been stable for at least one month prior to screening 
and may be continued throughout the study 
• Proton Pump Inhibitors (PPis) 
• Antihistamines 
• Intermittently used NSAIDS 
• Acetaminophen if medically necessary (not more than 
2 g/day) 
• Exceptions may be allowed on a case by case basis 
8. Subjects who have a  known allergy or sensitivity to 
zolmitriptan or its derivatives or formulations 
9. Known allergy or sensitivity to tapes, adhesives, or 
zolmitriptan 
10. Regular or recent intake of prescription drugs, particularly 
drugs with an influence on blood pressure 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 12 of 69 
 
11. Use of any other investigational compound within 
one month of planned study drug dosing  
12. On-going drug or alcohol abuse, or history of either deemed 
to be clinically significant by the investigator  
13. Systolic BP (measured after remaining sitting for 5 minutes) 
greater than 140 mmHg and diastolic BP greater than 
90 mmHg 
14. History of nasal pathology (e.g., polyps) or abnormal nasal 
exam  
15. Body Mass Index (BMI) greater than 35 kg/m2 
16. If, in the opinion of the investigator, the subject is not 
suitable for the study 
17. Any positive urine drug screen result or alcohol breath test 
CENTERS  
Single center 
STUDY DURATION  
Screening is 1 day (up to 30 days prior to dosing); in-clinic 
duration of study participation for each subject is approximately 
2 weeks total (includes 4 treatment periods), and the final end of 
study visit occurs on one day.  
PROCEDURES & 
ASSESSMENTS  
• Physical examination (Screening, 12 hour post drug 
administration and end of study/or early termination visit) 
• Clinical laboratory tests (Screening, and end of study/or 
early termination visit) 
• Collection of blood samples (pre-dose, 2, 5, 10, 15, 20, 30, 
45, 60, 90 min, 2 hr, 4 hr, 8 hr, 12 hr and 24 hr post-dose) 
for pharmacokinetics determination 
• Patch adhesion assessment at the time of application and at 
30 min and 60 min post-dose (for 60 min wear time 
treatment group only) 
• Vital signs (Screening, pre-dose and 10 min, 60 min, 2 hr, 
4 hr, 12 hr post-dose, and end of study/or early termination 
visit) 
• 12-lead ECGs (Screening, pre-dose, 15 min, 60 min, 8 hr, 
12 hr post-dose, and end of study/or early termination visit) 
• Investigator visual skin assessment of the M207 application 
site at 30 min (for 30 min wear time treatment group only), 
60 min (for 60 min wear time treatment group only), 12 hr, 
24 hour post-dose, and end of study/or early termination 
visit  


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 13 of 69 
 
• Residual zolmitripan swabbing on the skin at 30 min or 60 
min (depending on wear time assignment) 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 14 of 69 
 
1 
INTRODUCTION 
1.1 
Background 
Zosano Pharma has developed a zolmitriptan intracutaneous microneedle system as a potential 
therapy for the acute treatment of migraine.  To date, two trials have been completed, a 
pharmacokinetic study in healthy volunteers, and a single treatment efficacy and safety study in 
subjects with migraine. A long-term safety study is ongoing.  In all studies, the M207 system 
(“patch”) was applied to the upper arm for 30 minutes. 
1.2 
Investigational Products 
1.2.1 M207 Intracutaneous Microneedle System 
The Zosano M207 Intracutaneous Microneedle System is a novel drug delivery technology 
which consists of a disposable titanium patch centered on an adhesive backing with microneedles 
that are dry-coated witih the drug product formulation, and a reusable handheld applicator that 
ensures that the patch is applied with a defined application speed and energy to the site of 
administration.  
M207 systems consist of zolmitriptan coated titanium array with an adhesive backing that is 
applied using proprietary patch applicators.  Descriptions of the 1.9 mg patches used in the study 
are described below. 
1.2.2 Zolmitriptan Nasal Spray 
Zolmitriptan nasal spray is a commercially available product (Zomig® Nasal Spray) and will be 
purchased for use in this study.  The dose used in this study will be 2.5 mg/0.1 ml.  This dose 
should be administered to either the right or left nostril with the subject’s head tilted slightly 
backward. 
M207 1.9 mg Patch  
The M207 1.9 mg consists of a 3 cm2  titanium array of microprojections that are nominally 
340 µm in length coated with 1.9 mg of zolmitripan.  The array is applied to the center of a 5 cm2 
tan adhesive patch.  The patch is attached to the interior of a white to off-white polycarbonate 
ring co-molded with a desiccant, packaged in a cup. 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 15 of 69 
 
2 
STUDY OBJECTIVES 
The study objectives are as follows: 
To compare the pharmacokinetics, safety and tolerability of M207 3.8 mg administered to the 
upper arm to M207 3.8 mg administered to the thigh, particularly with respect to skin irritation 
(erythema, edema, bruising, bleeding). 
To compare the  pharmacokinetics, safety and tolerability of M207 3.8 mg worn for 30 minutes 
on the upper arm to M207 3.8 mg worn for 1 hour on the upper arm. 
To compare the pharmacokinetics, safety and tolerability of M207 3.8 mg to intranasal 
zolmitriptan 2.5 mg. 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 16 of 69 
 
3 
ETHICAL CONSIDERATIONS 
This study must be conducted in compliance with the protocol; the U.S. Code of Federal 
Regulations (CFR); the International Conference on Harmonisation (ICH-R) Good Clinical 
Practice (GCP) Guidelines; the Declaration of Helsinki (see Appendix 5); and all applicable 
federal, state and local laws, rules and regulations relating to the conduct of the study. 
3.1 
Institutional Review 
Prior to the initiation of clinical studies, the protocol, the Informed Consent Form (ICF), 
amendments to the protocol and ICF, advertisements and any other information for subjects will 
be reviewed and approved by Zosano Pharma and by the Independent Ethics Committee (IEC) of 
the participating study center in accordance with the CFR, the ICH-R and institutional EC 
policies.  All protocol amendments (See Section 11.1) and changes to the consent form occurring 
during the study must also be IRB/IEC approved. 
3.2 
Informed Consent 
Prior to study inception, each study participant or the legally authorized representative will be 
required to read, sign, and date an IRB/IEC approved ICF explaining the nature, purpose, 
possible risks and benefits of the study, and the duration of an individual’s participation in the 
study.  The clinical site personnel who conducted the informed consent discussion must also sign 
and date the consent form.  Each subject or legally authorized representative will be given a copy 
of the ICF. 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 17 of 69 
 
4 
INVESTIGATIONAL PLAN 
4.1 
Overall Study Design 
This is a single-center, open-label, randomized, four-way crossover study.  Each subject will 
receive each of the four study treatments once, followed by in-clinic monitoring and extensive 
blood sample collection for pharmacokinetic analysis. 
Dosing will occur approximately 48 hours apart, until completion of dosing in randomized order 
per the treatment sequence tables.  Plasma samples from the dosing days will be sent to the 
analytical laboratory for analysis and tolerability for each of the dose levels will be summarized. 
After completion of the four dosing days, subjects will be assessed one final time and dismissed 
from the study. 
4.2 
Endpoints 
The endpoints of the study are: 
Safety and Tolerability 
• Incidence of adverse events  
• Change in physical exam findings from pre-dose to 12 hours post-dose  
• Changes in vital signs from pre-dose to 10 min, 60 min, 2 hour, 4 hour, and 12 hour 
post-dose  
• Changes in ECG parameters from pre-dose to 15 min, 60 min, 8 hour, and 12 hour 
post-dose  
• Scores from a investigator visual skin assessment for erythema, edema, bruising and 
bleeding at the patch application sites from pre-dose to 30 min (for 30 min wear time 
treatment assignments only), 60 min (for 60 min wear time treatment assignment only), 
12 hour and 24 hour post-dose 
• Patch adhesion score at time of application at 30 min and 60 min post-dose (for 60 min 
wear time treatment assignment only) 
Pharmacokinetics 
• Cmax - maximum observed plasma concentrations 
• Tmax - time to maximum concentration 
• AUC0-last - the area under the plasma concentration time profile from hour 0 to the last 
detectable concentration at time t will be determined by the linear trapezoidal method. 
• AUC0-30min - the area under the plasma concentration time profile from minute 0 to 
minute 30 will be determined by the linear trapezoidal method. 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 18 of 69 
 
• AUC0-60min - the area under the plasma concentration time profile from minute 0 to 
minute 60 will be determined by the linear trapezoidal method. 
• AUC0-120min - the area under the plasma concentration time profile from minute 0 to 
minute 60 will be determined by the linear trapezoidal method. 
• k - apparent elimination rate constant will be estimated by linear regression of the 
log-transformed plasma concentrations during the terminal log-linear decline phase. 
• t1/2 - apparent half-life (t1/2) values will be calculated as 0.693/k. 
• AUC0-inf - the AUC value extrapolated to infinity will be calculated as the sum of AUCt, 
and the area extrapolated to infinity, calculated by the concentration at time t (Ct) divided 
by k. 
• Frel - bioavailability relative to other treatment sites of application and wear times 
4.3 
Safety Considerations 
M207 consisting two patches each 1.9 mg (3.8 mg), 30 minute upper arm application, has been 
studied in healthy volunteers (in clinic) and subjects with migraine (outpatient).  This regimen 
has been generally well-tolerated, with adverse events observed (dizziness and chest tightness) of 
those typically reported for triptans.  Adverse events reported were almost always within the first 
few minutes after patch application.  It is anticipated that systemic exposure with forearm 
application will be not significantly different than that seen with upper arm application, based on 
our experience with glucagon.  Also, since Cmax was generally observed, on average, at around 
15 minutes, wearing the patches for 1 hours will probably not be associated with higher Cmax 
levels than 30 minutes and should not result in different tolerability issues. 
4.4 
Study Population 
The study population will consist of 24 healthy volunteers (12 women and 12 men) 18 to 
50 years of age in general good health. 
4.4.1 Inclusion Criteria: 
1. Women or men 18 to 50 years of age. 
2. Good general health with no clinically significant abnormalities as determined by medical 
history, physical examination, CBC, blood chemistry, urinalysis, and ECG. 
3. Negative urine drug and alcohol screens and negative serum pregnancy tests (for female 
subjects) at screening. 
4. Consent of female subjects to use a medically effective method of contraception throughout 
the entire study period and for 30 days after the subject completes the study.  Medically 
effective methods of contraception that may be used by the subject include abstinence, use of 
diaphragm and spermicide, intrauterine device (IUD), condom and vaginal spermicide, 
hormonal contraceptives (subjects must be stable on hormonal contraceptives for at least the 
prior 3 months), surgical sterilization, and post-menopausal (≥ 2 years of amenorrhea). 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 19 of 69 
 
5. Ability to read, understand, and provide written informed consent that they understand the 
purpose of the study and procedures required for the study before enrolling in the study, and 
willingness to comply with all study procedures and restrictions. 
4.4.2 Exclusion Criteria: 
1. Evidence of significant history of hepatic, reproductive, gastrointestinal, renal, bleeding, or 
hematological disorders including coagulation, pulmonary, neurological, respiratory, 
endocrine, or cardiovascular system abnormalities (especially hypertension, peripheral 
vascular disease, coronary artery disease, transient ischemic attacks, or cardiac rhythm 
abnormalities), psychiatric disorders, acute infection, or other conditions that would interfere 
with study participation or with the absorption, distribution, metabolism, or excretion of 
drugs. 
2. Presence of two or more risk factors for cardiovascular disease (family history of premature 
heart disease, hyperlipidemia, or hypertension) 
3. Any contraindication to zolmitriptan administration including: 
• History of coronary artery disease or coronary vasospasm 
• Symptomatic Wolf-Parkinson-White syndrome or other cardiac accessory conduction 
pathway disorders 
• History of stroke, transient ischemic attack, or hemiplegic or basilar migraine 
• Peripheral Vascular Disease 
• Ischemic bowel disease 
• Uncontrolled hypertension 
• Any history of hepatic impairment 
4. History of contact dermatitis or known dermatological disorders that would interfere with the 
study procedures or assessments  
5. Planned participation in activities which cause inflammation, irritation, sunburn, lesions, or 
tattoos at the intended application sites from 2 weeks prior to screening through their last day 
of study participation 
6. Use of warfarin within 1 month prior to the first dose or heparin within 1 week prior to study 
drug administration 
7. Use of prescription and over the counter medications other than the following: 
• Hormone Replacement Therapy (HRT) 
• Birth control pills, patches, injections, or implants (all hormonal contraceptives) are 
allowed provided the dose has been stable for at least one month prior to screening and 
may be continued throughout the study 
• Antihistamines 
• Intermittently used NSAIDS 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 20 of 69 
 
• Acetaminophen if medically necessary (not more than 2 g/day) 
• Exceptions may be allowed on a case by case basis 
8. Subjects who have a  known allergy or sensitivity to zolmitriptan or its derivatives or 
formulations 
9. Known allergy or sensitivity to tapes, adhesives, or zolmitriptan 
10. Regular or recent intake of prescription drugs, particularly drugs with an influence on blood 
pressure. 
11. Use of any other investigational compound within one month of planned study drug dosing  
12. On-going drug or alcohol abuse, or history of either deemed to be clinically significant by the 
investigator  
13. Systolic BP (measured after remaining sitting for 5 minutes) greater than 140 mmHg and 
diastolic BP greater than 90 mmHg at screening 
14. History of nasal pathology (e.g., polyps) or abnormal nasal exam 
15. Body Mass Index (BMI) greater than 35 kg/m2 
16. If, in the opinion of the investigator, the subject is not suitable for the study 
17. Any positive urine drug screen result or alcohol breath test 
4.5 
Early Termination 
Participation in the study is completely voluntary and a subject can choose to withdraw from the 
study at any time.  In addition, a subject can be withdrawn for any of the following reasons: the 
Principal Investigator decides that continuing the drug may be harmful, a subject is 
non-compliant with the protocol, a subject has a serious reaction to the treatment, or the study is 
stopped by the Independent Ethics Committee, US Food and Drug Administration (FDA), or 
Zosano Pharma. 
In order to complete all treatments for each dose, additional subjects may be enrolled to account 
for subjects who withdraw or are discontinued from the study.  If a subject does not complete all 
planned treatments, the reason and date of withdrawal from the study must be recorded in the 
CRF.  Zosano Pharma should be notified immediately if a subject withdraws prematurely from 
the study. 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 21 of 69 
 
5 
STUDY TREATMENTS 
5.1 
Study Drug Treatments 
The treatments are: 
• Treatment A: M207 3.8 mg administered as two 1.9 mg patches 30 min wear time (upper 
arm application) 
• Treatment B: M207 3.8 mg administered as two 1.9 mg patches 30 min wear time (thigh 
application) 
• Treatment C: M207 3.8 mg administered as two 1.9 mg patches 1 hour wear time (upper 
arm application 
• Treatment D: zolmitriptan nasal 2.5 mg (single dose) 
Depending on the treatment assignment, two M207 patches will be applied to the upper arm 
(shoulder area) or thigh by means of a handheld reusable applicator with an application energy of 
0.26 Joules.  Used patches will be removed 30 or 60 minutes after application, depending on the 
treatment wear time assignment.  The patches will be collected and frozen in storage until 
shipped for analysis of remaining drug.  
The applicator systems and unused patches should be stored at room temperature, not to exceed 
15-30°C (59-86°F).  Unused patches should not be refrigerated or frozen. 
5.2 
Study Treatment Assignment and Schedule 
The 24 subjects are planned to receive each of the four treatments (A, B, C, D) 48 hours apart.  
Subjects will be randomly assigned to one of 4 treatment sequences. 
At the end of each dosing day, the safety data from the subjects will be evaluated.  If tolerability 
is deemed to be acceptable by the Principal Investigator, a decision will be made to proceed to 
the next dosing day. 
5.3 
Study Treatment Accountability Procedures 
All transdermal M207 Patch System components are to be used only in accordance with this 
protocol under the supervision of the Investigator.  The Investigator will maintain detailed and 
verifiable records that document the receipt, storage, dispensing, and return of all M207 Patch 
System components provided by Zosano Pharma.  These records will include a listing of which 
study drug supplies were dispensed for particular subjects treated in the study, by whom, when, 
and the specific quantities dispensed and remaining at the completion of the subject’s 
investigational treatment.  Reasons for departure from the expected dispensing and dosing 
regimen will also be documented.  All left over used and unused study patches should be 
retained for drug accountability auditing to be performed by Zosano Pharma or its 
representatives.  At the conclusion of the study, the study drug accountability records must 
accurately reflect the receipt and final disposition of all study drug shipped to the site.  


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 22 of 69 
 
Destruction or return of remaining used and unused drug supplies by the study site will occur 
only upon receipt of written authorization by Zosano Pharma or its representatives. 
5.4 
Prior and Concomitant Medications Allowed and prohibited During the Study 
Subjects will be asked to refrain from taking either prescription or OTC medications from the 
time of Screening until the completion of the study, except for those discussed in this section.  
All concomitant medications taken during the study will be recorded on the concomitant 
medications case report form (CRF) with indication for use, totally daily dosage, and dates of 
drug administration. 
Subjects must discontinue use of herbal or over-the-counter medications (with the exception of 
all medications listed below) for 48 hours prior to treatment days and throughout the study. 
Allowed prescription and over the counter medications: 
• Hormone Replacement Therapy (HRT) 
• Birth control pills, patches, injections, or implants (all hormonal contraceptives) are 
allowed provided the dose has been stable for at least one month prior to screening and 
may be continued throughout the study 
• Intermittently used NSAIDS 
• Acetaminophen may be administered if medically necessary (not more than 2 g/day) 
• Antihistamines 
All other concomitant medications will be prohibited, except as specifically exempted by the 
Sponsor on a case-by-case basis. 
Excluded prescription medications: 
Regular or recent intake of prescription drugs, particularly drugs with an influence on blood 
pressure are excluded. 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 23 of 69 
 
6 
STUDY VISIT SCHEDULE AND ASSESSMENTS 
Following review of all Screening procedures, eligible subjects will be enrolled into the dosing 
phase of the study.  The interval between screening and first treatment may be up to 30 days.  
Eligible subjects will check into the clinic on the day before each treatment and are required to 
stay approximately 36 hours at the clinic for preparation, dosing and follow-up assessments for 
each dosing period.  The washout period following each dose must be a minimum of 48 hours 
until the next dose.  Subjects will be required to stay in the clinic for the entire duration of the 
study (unless medically necessary to leave the clinic as instructed by the principal investigator). 
All procedure times listed are approximate and are provided as a guide.  The PK samples should 
be drawn as close as possible to the specified time. Vital signs should be taken within a time 
frame that will allow the PK blood sample to be drawn on schedule.  Actual times of procedures 
for each subject may vary depending on scheduling and will be recorded on the CRF. 
Subjects will refrain from smoking or using tobacco products during each clinic stay.  
Consumption of unsweetened coffee and tea in moderate amounts will be permitted.  Breakfast 
can be served approximately two hours post-dosing, lunch approximately 4-6 hours after dosing 
and dinner will be served approximately 8-10 hours after dosing. 
AEs and concomitant medication usage will be assessed throughout the study from the first day 
of study patches application until the Final Visit (or Early Termination) procedures are 
completed. 
6.1 
Screening 
All Screening procedures will be performed after obtaining informed consent and should be 
completed within 30 days prior to admission for the first of four sequential treatments within the 
study.  Subjects who are not dosed within 30 days after signing the ICF must be re-assessed for 
eligibility.  The screening procedures include: 
6.1.1 Screening Visit (Day -30 to -1) 
Subjects who are considered to be good candidates for the study will be seen in the clinic and 
have the following procedures performed: 
• Obtain informed consent 
• Obtain a medical history and demographics 
• Record concomitant medications 
• Perform a physical examination 
• Measure Vital signs (inclusive of temperature) 
• Measure height 
• Measure body weight and calculate BMI 
• Confirm eligibility 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 24 of 69 
 
• Collect blood and urine samples for clinical laboratory tests 
• Perform serum pregnancy test (for all females) 
• Collect blood for serology (HIV, Hepatitis B, Hepatitis C) 
• Perform urine drug and alcohol (breath) testing 
• Record a 12-lead ECG 
Medical history, physical examination, ECG and laboratory findings are to be reviewed, and 
eligibility determined.  The sponsor must approve any exception to the inclusion or exclusion 
criteria before planned admission for dosing. 
A subject number will be assigned when the subject signs the informed consent.  Only subject 
number, initials and date of birth will identify subjects to the Sponsor.  In the event that a subject 
who has signed the informed consent but did not receive a dose of study medication experiences 
an SAE, the following information will be captured: demographic data (initials, age, and race), 
all other Screening assessments that have been completed, AE(s), and concomitant 
medication(s). 
6.2 
Admission/baseline (Day Before Each Dose) 
If subjects continue to meet all entry criteria the day prior to each dosing, the subject will stay in 
the clinic overnight.  The following procedures will be performed the day prior to each dosing: 
• Record concomitant medications 
• Perform urine drug and alcohol (breath) testing 
• Urine pregnancy test (all women) 
• Collect temperature 
• Confirm eligibility 
Standardized meals and beverages will be served the evening prior to dosing and will be 
provided by the clinical site.  Subjects should complete their dinner by 10 p.m.  Subsequently, 
subjects will fast overnight and receive only clear liquids after 10 p.m.  


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 25 of 69 
 
6.3 
Study Dosing Days 
General Considerations 
Subjects will fast during the night preceding dosing and until 2 hours after dosing.  Water is 
allowed ad libitum, as well as tea and coffee in moderate amounts. 
The following morning (between 0630 and 0930) they will receive that day’s scheduled 
treatment (A, B, C or D).  Breakfast should be withheld until two hours post-dosing.   
On all study treatment days, an intravenous cannula may be inserted to aid blood sampling.  The 
cannula may be replaced as needed on subsequent study days at the discretion of the Investigator. 
All AEs, including any skin irritations and sensations as well as concomitant medication usage 
will be documented. 
When multiple assessments are required at the same time point, they will be conducted in the 
order as specified in the footnotes of the schedule of events.  All procedures should be performed 
relative to “Time 0” (patch application) when a time is listed. 
6.3.1 Dosing Visit (all Periods) – All Treatments 
The following procedures will be performed on each of the four dosing days.  The actual 
procedures will be identical at each of the dosing days, only the study drug administered on each 
of the treatment days will vary. 
6.3.1.1 Pre-Dose - Before treatment Administration on the Day of Dosing 
• Record concomitant medications 
• Confirm eligibility 
• Measure vital signs 
• Record a 12-Lead ECG 
• Investigator visual skin and nasal assessment (visual inspection) 
• Determine that subject is stable and in good health and appropriate for dosing 
• Collect blood for a PK sample within 15 minutes prior to administering study drug 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 26 of 69 
 
6.3.1.2 Treatment Administration (t = 0) 
• Apply patches or administer intranasal zolmitriptan (see Appendix 1 for instructions on 
patch administration) 
• Begin recording all AEs, whether observed by investigator, reported by the subject, 
observed in laboratory findings, or discovered by other means, on the AE CRF through 
the End of Study (or Early Termination) final visit.  All adverse events must be followed 
to resolution. 
• Record patch adhesion score 
6.3.1.3 2 Minutes after Treatment Administration 
• Collect blood for a PK sample 
• Record concomitant medications 
6.3.1.4 5 Minutes after Treatment Administration 
• Collect blood for a PK sample 
• Record concomitant medications  
6.3.1.5 10 Minutes after Treatment Administration 
• Collect blood for a PK sample 
• Measure vital signs 
• Record concomitant medications  
6.3.1.6 15 Minutes after Treatment Administration 
• Collect blood for a PK sample 
• Record a 12-Lead ECG 
• Record concomitant medications  
6.3.1.7 20 Minutes after Treatment Administration 
• Collect blood for a PK Sample 
• Record concomitant medications  
6.3.1.8 30 Minutes after Treatment Administration 
• Collect blood for a PK sample 
• Record concomitant medications and adverse events 
• Record patch adhesion score  
• Remove patches and perform the following procedures in the order listed below (for 30 
minute wear time treatment assignment only): 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 27 of 69 
 
• Investigator visual skin assessment of the patch application sites  
• Retain and package patches for freezing. Refer to full instructions in Appendix 3.  
• Application site swabbing. Refer to full instructions in Appendix 3.  
6.3.1.9 45 Minutes after Treatment Administration 
• Collect blood for a PK sample 
• Record concomitant medications  
6.3.1.10 60 Minutes after Treatment Administration 
• Collect blood for a PK sample 
• Measure vital signs 
• Record a 12-lead ECG 
• Record concomitant medications and adverse events 
• Record patch adhesion score (60 minute wear time assignment only) 
• Remove patches and perform the following procedures in the order listed below (for 60 
min wear time assignment only): 
• Investigator visual skin assessment of the application sites  
• Retain and package patches for freezing. Refer to full instructions in Appendix 3.  
• Application site swabbing. Refer to full instructions in Appendix 3.  
6.3.1.11 90 Minutes after Treatment Administration 
• Collect blood for a PK sample 
• Record concomitant medications  
6.3.1.12 Two Hours after Treatment Administration 
• Collect blood for a PK sample 
• Measure vital signs 
• Record concomitant medications  
6.3.1.13 Four Hours after Treatment Administration 
• Collect blood for a PK sample 
• Measure vital Signs 
• Record concomitant medications  
6.3.1.14 Eight Hours after Treatment Administration 
• Collect blood for a PK Sample 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 28 of 69 
 
• Record a 12-Lead ECG 
• Record concomitant medications  
6.3.1.15 Twelve Hours after Treatment Administration 
• Collect blood for a PK Sample 
• Measure vital Signs 
• Record a 12-Lead ECG 
• Determine if subject is stable for the next dosing period  
• Investigator visual skin assessment of the application sites 
• Perform a physical examination 
• Record concomitant medications and adverse events 
6.3.1.16 Twenty Four Hours after Treatment Administration 
• Collect blood for a PK Sample 
• Record concomitant medications and adverse events 
• Investigator visual skin assessment of the application sites 
6.3.1.17 Zolmitriptan PK Sample Handling 
Details related to zolmitriptan PK sample collection and shipment is provided in Appendix 2. 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 29 of 69 
 
6.4 
End of Study Visit/or Early Termination  
• Within 48 hours after completion of all protocol required procedures on the last dosing 
day, subjects will complete an End of Study Visit.  At that time, the following 
assessments will be performed: 
• Record all AEs, whether observed by investigator, reported by the subject, observed in 
laboratory findings, or discovered by other means, on the AE CRF through the end of 
study final visit. 
• Record a 12-Lead ECG 
• Record any new concomitant medications and adverse events 
• Measure vital signs (inclusive of temperature) 
• Perform a physical examination 
• Measure body weight 
• Investigator visual skin assessment of the application sites 
• Collect blood and urine for laboratory tests and serum pregnancy test (for all females) 
• Dismiss subject from the study 
6.5 
Post Study Phone Call - Follow-up on Adverse Events 
Subjects must be called within 5-10 days following the day of discharge to follow-up on 
resolution of all ongoing AEs.  
6.6 
Early Termination 
Subjects who terminate early will complete the assessments normally scheduled for the End of 
Study Visit (see above). 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 30 of 69 
 
7 
STUDY PROCEDURES 
7.1 
General Confinement Restrictions 
Alcohol is prohibited 24 hours before study drug administration until discharge from the clinic. 
Subject will not engage in any activity that may cause inflammation, irritation, sunburn, lesions 
or tattoos at the intended application sites from 2 weeks prior to Screening through their last day 
of study participation.  Subject will not engage in strenuous activity at any time during their stay 
at the clinical unit.  Subjects will be required to stay in the clinic for the entire duration of the 
study (unless medically necessary to leave the clinic as instructed by the principal investigator). 
7.2 
Collection, Processing and Assay of Samples 
Blood sampling will be performed at several close time points throughout the study therefore the 
study center may utilize an IV cannula.  After blood sampling, the cannula will be flushed with 
saline.  
Each of the plasma samples collected for pharmacokinetic analysis will be separated into two 
containers.  One of the samples will be sent to the analytical laboratory for analysis and one 
sample will be maintained at the investigative site.  The plasma sample retained at the site may 
be used for further analysis (additional metabolites, etc.) at some future timepoint. 
Subjects who complete all four treatments will have a blood draw volume of approximately 
395 mL for the entire duration of the study (See Table below). 
Blood Volume Requirements (mL) 
Purpose 
Expected Number 
Sample Amount 
(in mL) 
Total Amount 
(in mL) 
Clinical laboratory tests 
(blood chemistry) 
2 
8.5 
17.0 
Hematology and Serum 
Pregnancy 
2 
4.0 
8.0 
PK 
60 (15 samples per period x 
4 periods) 
4.0  
240.0 
60 (discard volume with 
cannula flush) 
2.0 
120.0 
Serology (screen only) 
1 
10.0 
10.0 
GRAND TOTAL  
395 mL 
 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 31 of 69 
 
7.3 
Assessment Details 
7.3.1 Clinical Laboratory Tests 
Standard clinical laboratory tests (serum pregnancy for all women, CBC, hematology, and 
urinalysis) will be performed at Screening and End of Study (or early termination) and urine 
pregnancy testing for all women at each Admission/baseline visit.   
A blood sample at screening will be taken to perform serological tests for HIV, Hepatitis B and 
Hepatitis C. 
CBC will include the following: Hematocrit, hemoglobin, red blood cell count, white blood cell 
count with differential, platelets, mean corpuscular volume, mean corpuscular hemoglobin, and 
mean corpuscular hemoglobin concentration. 
Blood hematology will include the following: Urea, glucose, aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), alkaline phosphatase (AP), lactate dehydrogenase (LDH), 
sodium, phosphate, potassium, chloride, creatinine phosphokinase (CPK), globulin, cholesterol, 
creatinine, serum calcium, total bilirubin, triglyceride, cholesterol (HDL and LDL), gamma 
glutamyl transpeptidase (GGT) and uric acid. 
Urinalysis will include the following: bilirubin, blood, glucose, ketones, leuokocyte esterase, 
nitrite, pH, protein, specific gravity, and urobilinogen.  Microscopic examination will be 
conducted if protein, leukocyte esterase, nitrite and/or blood are detected.  
Urine drug screen and alcohol (breath) testing will be performed at screening and each 
Admission/baseline visit.  Urine drug screen will test for amphetamine, barbituates, cocaine, 
cannabinoids, phencyclidine (PCP), opioids, and methamphetamines. 
Samples will be analyzed by a local laboratory.  After reviewing the laboratory reports and 
evaluating the results, the Investigator must review, sign/date the laboratory report.  
7.3.2 Vital Signs 
Vital signs include heart rate, pulse, respiratory rate, as well as systolic and diastolic arterial 
pressure.  Vital signs will be recorded after subjects have been in the seated resting position for 2 
minutes.  Temperature will be taken at Screening, admission/baseline, and at end of study visit/or 
early termination only. 
7.3.3 Electrocardiograms 
A standard 12-lead ECG will be performed by a qualified individual at the site.  General 
morphology and intervals [Heart rate, QRS, PR interval, QRS, QTn, QTcf], of interest will be 
assessed with each tracing.  The principal or sub-investigator must review the tracing and assess 
it for any clinically significant abnormality.  Any clinically significant abnormality noted at the 
time of screening on the ECG will be recorded in the appropriate source document and may 
result in the exclusion of the subject from the study. 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 32 of 69 
 
7.3.4 Investigator Visual Skin Assessments of the Application Sites 
Each M207 patch site (where a patch has been removed) will be observed for the following skin 
assessments pre-dose and immediately after removal of the patches from the subject’s skin (and 
before swabbing) at 30 min (for 30 min wear time treatment groups only), 60 min, 12 hr, 24 hr 
and at the End of Study/or Early Termination visit. 
7.3.4.1 Erythema 
The erythema evaluations will be performed using the following scale: 
• 0 = None 
• 1 = Mild redness 
• 2 = Moderate colored redness 
• 3 = Beet colored redness 
7.3.4.2 Edema 
The edema evaluations will be performed using the following scale: 
• 0 = None 
• 1 = Slight edema 
• 2 = Moderate edema 
• 3 = Severe edema 
7.3.4.3 Bruising  
Bruising assessments (visual rating) will be performed using the following scale: 
• 0 = None 
• 1 = ≤ 25% application site has bruising spots 
• 2 = ≥ 26 to ≤ 50% application site has bruising spots 
• 3 = > 50% application site has bruising spots 
7.3.4.4 Bleeding  
Bleeding will be assessed using the following scale: 
• 0 = None 
• 1 = Pink color on skin 
• 2 = Visible blood drop 
• 3 = Active bleeding 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 33 of 69 
 
7.3.5 Residual Drug on Used M207 Patches 
The used patches should be placed in the proper cryovial tube provided by Zosano and 
immediately placed on dry ice or frozen at approximately -80°C (plus or minus 10°C) and kept 
frozen until shipment to the bioanalytical lab.  Used patches may be assayed for residual 
zolmitriptan if considered relevant after review of the pharmacokinetic results.  Instructions for 
removing and storing the patches are provided in Appendix 3. 
7.3.6 Residual Drug on Skin after M207 Patch Removal 
At the time patches are removed (for all patch treatment groups), the M207 patch skin sites will 
be swabbed to collect any residual drug that may be on the skin surface where a transdermal 
M207 patch has been applied.  The process consists of using 3 swabs to capture the drug residual 
for each patch site.  The procedure is described in Appendix 3.   
7.3.7 Patch Adhesion Assessment  
For each assessment, investigators should use a 5-point numerical scale in which each score 
corresponds to a specified range of adhered surface area of each patch, as follows: 
0 = ≥ 90% adhered (essentially no lift off the skin) 
1 = ≥ 75% to < 90% adhered (some edges only lifting off the skin) 
2 = ≥ 50% to < 75% adhered (less than half of the patch lifting off the skin) 
3 = > 0% to < 50% adhered (not detached, but more than half of the patch lifting off the skin 
without falling off) 
4 = 0% adhered (patch detached; completely off the skin) 
7.3.8 Recording Adverse Events 
Adverse events are collected from the time of of first patch application until the end of the study.  
A detailed discussion regarding the collection and reporting of adverse events is provided in 
Section 8.  


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 34 of 69 
 
8 
ADVERSE EVENTS 
All skin and systemic AEs, regardless of treatment group or suspected causal relationship to the 
investigational products, will be reported as described in the following sections. 
For all AEs, the Investigator must pursue and obtain information adequate both to determine the 
outcome of the AE and to assess whether it meets the criteria for classification as a SAE 
requiring immediate notification of the Sponsor.  For all skin and AEs, sufficient information 
should be obtained by the Investigator to determine the causality of the AE.  The Investigator is 
required to assess causality.  For skin and systemic AEs with a causal relationship to the 
investigational product, follow-up by the Investigator is required until the event or its sequelae 
resolve or stabilize at a level acceptable to the Investigator, and Zosano Pharma concurs with that 
assessment. 
Reporting Period 
Collection of skin and systemic AEs will be initiated from the time of treatment application and 
will conclude when the end of study procedures for the fouth treatment are completed (or Early 
Termination).  The Investigator will also report to the Sponsor all SAEs that come to his/her 
attention after the study termination within 30 days of the last dose of study drug. 
Any SAE occurring any time after the reporting period must be promptly reported if a causal 
relationship to the investigational product is suspected. 
8.1 
Adverse Event Definitions 
An AE is any untoward medical event that occurs in a clinical investigation, where a subject is 
administered a product or medical device, without regard to causal relationship between the 
event and the treatment.  An AE can be any unfavorable and unintended sign or symptom, 
including clinically significant laboratory values and test results, concomitant illness, accident, or 
worsening of an existing medical condition. 
Information about all adverse events, whether volunteered by the subject, discovered by 
investigator questioning, or detected through physical examination, laboratory or other means, 
will be collected and recorded on the Adverse Event CRF using the signs, symptoms or diagnosis 
associated with them and followed until resolution or, in the Investigator’s opinion, a stable 
condition is reached, or until the patient is lost to follow up. 
Medical conditions/diseases present before starting study treatment are only considered adverse 
events if they worsen after starting study treatment. 
In the event of a clinically important AE, a serum sample may be collected as soon as possible 
after the occurrence of the event for drug assay or for additional laboratory tests.  The 
Investigator will ensure that the serum sample is properly labeled and stored.  The Investigator 
and other study personnel responsible for the care of the patient will institute any supplementary 
investigations of significant AEs based on the clinical judgment of the likely causative factor(s).  
This may include seeking further opinion of a specialist in the field of the AE. 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 35 of 69 
 
Any abnormal lab tests starting from the day of study patch application that are clinically 
significant, as determined by the Investigator, should be reported as AEs if: 
• the test result is associated with accompanying symptoms; 
• the test result requires additional diagnostic testing or medical/surgical intervention; 
• the test result leads to a change in study dosing or discontinuation from the study, 
significant additional concomitant drug treatment, or other therapy; 
• the test result is considered to be an AE by the Investigator or sponsor 
Merely repeating an abnormal test, in the absence of any of the above conditions, does not 
constitute an AE.  Any abnormal test result that is determined to be an error does not require 
reporting as an AE. 
8.2 
Documentation and Reporting of Adverse Events By the Investigator 
All adverse events (AEs) occurring after the application of the first dose through the End of 
study visit/or early termination, will be reported on the AE CRF pages.  Based on the medical 
judgement of the investigator, all non-serious systemic and skin AEs will be followed until 
30 days after the final end of study visit.  All non-resolved, non-serious systemic and skin AEs 
beyond such date will be recorded as ‘ongoing’ without further follow up. 
However, an AE form will not be filled out for subjects who sign the ICF but fail the entry 
criteria (Screening failures) during the Screening process and experience a non-serious AE. 
Application site reactions will be reported on a dedicated assessment form for the visual skin 
assessment of the application sites.  The regular AE form does not have to be completed for such 
events unless the events are not covered by the questions on the visual skin assessment form or 
are reported outside their time window.  However, all such events will be included in the 
analyses of adverse event incidence. 
Each AE, including skin AEs, is to be assessed to determine if it meets the criteria for an SAE.  
If an SAE occurs, expedited reporting will follow local and international regulations, as 
appropriate (See Section 8.4).  It should be noted that the form for collection of SAE information 
is not the same as the AE CRF.  Where the same data are collected, the forms must be completed 
in a consistent manner.  For example, the same AE term should be used on both forms.  Systemic 
and skin AEs should be reported using concise medical terminology on the CRF pages as well as 
on the form for collection of SAE information. 
In addition to recording the signs, symptoms or diagnosis associated with them to describe the 
adverse event, the following will also be assessed and recorded: 
8.2.1 Duration 
Record the start date and time of the event, and, if applicable, the end date and time.  If the event 
is still ongoing at the final or early termination visit or after the end of follow-up, this should also 
be recorded. 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 36 of 69 
 
8.2.2 Severity Ratings 
The Investigator will evaluate the severity of each AE using the following definitions: 
• Mild - event may be noticeable to patient; does not influence daily activities; usually does 
not require intervention. 
• Moderate - event may be of sufficient severity to make patient uncomfortable; 
performance of daily activities may be influenced; intervention may be needed. 
• Severe - event may cause severe discomfort; usually interferes with daily activities; 
patient may not be able to continue in the study; treatment or other intervention usually 
needed. 
Note the distinction between the severity and the seriousness of an AE.  A severe event is not 
necessarily an SAE.  For example, a headache may be severe (interferes significantly with 
patient's usual function) but would not be classified as serious unless it met one of the criteria for 
SAEs, listed above. 
8.2.3 Relationship to Study Drug 
The Investigator’s assessment of causality must be provided for all systemic and skin AEs 
(serious and non-serious).  An Investigator’s causality assessment is the determination of 
whether there exists a reasonable possibility that the investigational product caused or 
contributed to an AE.  If the Investigator’s final determination of causality is unknown and the 
Investigator does not know whether or not the investigational product caused the event, then the 
event will be handled as “related to investigational product” for reporting purposes.  If the 
Investigator's causality assessment is "unknown but not related to investigational product", this 
should be clearly documented on study records. 
In addition, if the Investigator determines an SAE is associated with study procedures, the 
Investigator must record this causal relationship in the source documents and CRF, as 
appropriate, and report such an assessment in accordance with the SAE reporting requirements, 
if applicable. 
After careful medical consideration, the Investigator will evaluate the relationship of each AE to 
study drug applying the following definitions: 
Probably Related: 
An AE that is likely due to the use of the study drug.  The relationship in 
time may be suggestive.  An alternative explanation is less likely, 
e.g., concomitant drug(s), concurrent disease(s). 
Possibly Related: 
An AE that may or may not be due to the use of the study drug.  The 
relationship in time is reasonable; therefore, a causal relationship cannot 
be excluded.  An alternative explanation is inconclusive, e.g., concomitant 
drug(s), concurrent disease(s). 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 37 of 69 
 
Not Related: 
An AE that is judged to be clearly due only to extraneous causes (disease, 
environment, etc.).  The cause must be noted on the AE CRF page. 
8.3 
Serious Adverse Event Definitions 
A serious adverse event (SAE) or reaction is any untoward medical occurrence that at any dose: 
• Results in death; 
• Is life-threatening (immediate risk of death); 
• Requires inpatient hospitalization or prolongation of existing hospitalization; 
• Results in persistent or significant disability/incapacity; or 
• Is a congenital anomaly/birth defect. 
Important medical events that may not result in death, be life-threatening, or require 
hospitalization may be considered an SAE when, based upon appropriate medical judgment, they 
may jeopardize the patient and may require medical or surgical intervention to prevent one of the 
outcomes listed in this definition. 
Definition of disability: A substantial disruption of a person’s ability to conduct normal life 
functions. 
Life-threatening SAE: Any AE that places the patient, in the view of the Investigator, at 
immediate risk of death from the reaction as it occurred (i.e., it does not include a reaction that 
had it occurred in a more severe form, might have caused death). 
Hospitalization: AEs reported from clinical trials associated with hospitalization or prolongation 
of hospitalization is considered serious.  Hospitalization does not include the following: 
• Rehabilitation facilities; 
• Hospice facilities; 
• Respite care (e.g., caregiver relief); 
• Skilled nursing facilities; 
• Nursing homes; 
• Routine emergency department admissions; or 
• Same day surgeries (as outpatient/same day/ambulatory procedures). 
Hospitalization or prolongation of hospitalization in the absence of a precipitating, clinical AE is 
not in itself an SAE.  Examples include: 
• Admission for treatment of a preexisting condition not associated with the development 
of a new AE or with a worsening of the preexisting condition (e.g., for work-up of 
persistent pre-treatment lab abnormality); 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 38 of 69 
 
• Social admission (e.g., patient has no place to sleep); 
• Administrative admission (e.g., for yearly PE); or 
• Pre-planned treatments or surgical procedures that have been noted in the baseline 
documentation for the entire protocol and/or for the individual patient. 
Pregnancies, though not expected in this subject population, are to be reported as SAEs.  
Pregnancy follow-up should describe the outcome of the pregnancy, including any voluntary or 
spontaneous termination, details of the birth, the presence or absence of any congenital 
abnormalities, birth defects, maternal or newborn complications and their relation to the study 
treatment. 
Unexpected Adverse Events 
An unexpected AE is any AE, the specificity or severity of which is not consistent with the 
current Investigator brochure; or if an Investigator brochure is not required or available, the 
specificity or severity of which is not consistent with the risk information described in the 
general investigational plan or elsewhere in the current application, as amended. “Unexpected,” 
as used in this definition, refers to an AE that has not been previously observed (i.e., is not 
included in the Investigator brochure) rather than an event that is not anticipated based on the 
pharmacological properties of the pharmaceutical product. 
8.4 
Reporting Requirements For Serious Adverse Events 
ALL SERIOUS ADVERSE EVENTS, REGARDLESS OF CAUSE(S) OR RELATIONSHIP 
TO STUDY DRUG MUST BE REPORTED IMMEDIATELY TO THE SPONSOR BY 
TELEPHONE AND FAX. 
8.4.1 Sponsor SAE Contact Information 
Pete Schmidt, MD, MSc 
Phone/fax: 510-745-1251 
If an SAE occurs, the Sponsor is to be notified within 24 hours of awareness of the event by the 
Investigator.  In particular, if the SAE is fatal or life-threatening, notification to the Sponsor must 
be made immediately, irrespective of the extent of available AE information.  This timeframe 
also applies to additional new information (follow-up) on previously forwarded SAE reports. 
The Investigator must complete the SAE Report Form and send it along with other relevant 
source documents to the medical monitor within 24 hours.  For all SAEs, the Investigator is 
obligated to pursue and provide information to the medical monitor in accordance with the 
timeframes for reporting specified above.  The Investigator (or a physician on the investigational 
staff) must provide relationship to study drug as soon as possible and sign the SAE forms.  The 
Investigator must also provide any relevant information regarding the SAE and respond to 
requests for follow-up in a timely manner.  All SAEs will also be reported on the AE CRF page 
and CM administered in association with the SAE will be documented on the CRF. 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 39 of 69 
 
If an SAE occurs and comes to the attention of the Investigator after study termination within 
30 days of the last dose of study drug(s), it must be reported immediately to the sponsor in the 
same way as the SAEs occurring during the study. 
8.4.2 Follow up of Adverse Events 
All SAEs must be followed up until resolution or, in the Investigator’s opinion, a stable 
condition is reached, or until the patient is lost to follow up.  Based on the medical judgment of 
the Investigator, all non-serious systemic and skin AEs will be followed until 30 days after the 
last visit.  All non-resolved, non-serious systemic and topical AEs beyond such date will be 
recorded as “ongoing” without further follow up. 
 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 40 of 69 
 
9 
DATA MANAGEMENT 
9.1 
Data Collection 
Designated investigator staff must enter the information required by the protocol into the study 
CRF, whether paper or electronic on an ongoing basis.  The completed CRF pages will be 
reviewed against source documents by the monitor at each monitoring visit.  If any data, 
signatures, or forms are missing or incorrect, the Investigator will be informed and corrections 
made.  If paper CRF is used, they will be collected from the study site after monitoring visits and 
data queries are completed and the investigator has reviewed and signed off on each subject’s 
CRF certifying that the data are complete and accurate.  Electronic CRF require the same 
procedures for timely completion, transmittal, monitoring, query resolution and Investigator 
review as paper CRF and will meet all GCP/ICH-R requirements, including 21 CFR, Part 11 
regarding electronic records and signatures. 
9.2 
Database Management and Quality Control 
Study auditing, data entry, verification and validation of the database, and subsequent analysis 
will be performed by any or all of the sponsor's Clinical Research and Development, Clinical 
Pharmacology, Statistics, and Regulatory Compliance Departments or the sponsor’s 
representatives for these functions according to current GCP requirements.  In addition, 
computerized data entries will be checked against paper CRF if used.  If electronic CRFs are 
used, the system will meet all GCP/ICH-R requirements for database integrity, including 
21 CFR, Part 11. 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 41 of 69 
 
10 
STATISTICAL METHODS AND DATA ANALYSIS 
10.1 Sample Size Considerations 
No formal sample size calculation was performed.  In previous studies of Zosano Pharma 
transdermal products in healthy volunteers, a sample size of 24 was sufficient to provide 
directional information on tolerability, as well as adequate information on pharmacokinetics, and 
comparative pharmacokinetics for various regimens.  
10.2 Demographics and Baseline Characteristics 
Demographics and baseline characteristics will be summarized descriptively. 
10.3 Analysis Population and Handling of Drop-Outs 
All subjects who receive any amount of study drug will be included in the safety analyses (Safety 
Population).  The PK population will include all subjects who receive any amount of study drug 
and for whom the PK profile can be adequately characterized.  Drop-outs within a 24-hour 
period are not anticipated; however should they occur prior to 2 hours after patch application 
then additional eligible subjects may be enrolled. 
10.4 Zolmitriptan Pharmacokinetics 
Plasma zolmitriptan and n-desmethyl zolmitriptan concentrations as a function of time following 
M207 patch administration will be plotted by treatment.  The following pharmacokinetic 
parameters will be calculated for each treatment and subject with samples analyzed using each 
assay. 
• Cmax - maximum observed plasma concentrations 
• Tmax - time to maximum concentration 
• AUC0-t - the area under the plasma concentration time profile from hour 0 to the last 
detectable concentration at time t will be determined by the linear trapezoidal method. 
• AUC0-30min - the area under the plasma concentration time profile from minute 0 to 
minute 30 will be determined by the linear trapezoidal method. 
• AUC0-60min - the area under the plasma concentration time profile from minute 0 to 
minute 60 will be determined by the linear trapezoidal method. 
• AUC0-120min - the area under the plasma concentration time profile from minute 0 to 
minute 60 will be determined by the linear trapezoidal method 
• k - apparent elimination rate constant will be estimated by linear regression of the 
log-transformed plasma concentrations during the terminal log-linear decline phase. 
• t1/2 - apparent half-life (t1/2) values will be calculated as 0.693/k. 
• AUC0-inf - the AUC value extrapolated to infinity will be calculated as the sum of AUCt, 
and the area extrapolated to infinity, calculated by the concentration at time t (Ct) divided 
by k. 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 42 of 69 
 
• Frel - bioavailability relative to other treatment sites of application and wear times 
PK parameters (Cmax, Tmax, and AUCs) for M207 and intranasal zolmitriptan will be compared.  
Descriptive statistics (arithmetic and geometric means, standard deviation [SD], coefficient of 
varions [CV(%)], minimum [Min], maximum [Max], and median) of the plasma concentrations 
versus time will be presented.  Calculation of Tmax will start from the time of study drug 
administration.  Further details on the analysis of PK parameters can be found in the statistical 
analsyis plan. 
10.5 Analyses of Safety Data 
Verbatim AEs will be mapped to preferred term and body-organ system using MedDRA™.  The 
number and percentage of subjects reporting AEs will be summarized by AE preferred term and 
AE body-organ system.  Adverse events will be summarized by severity and relationship to 
study drug. 
Scores of the investigator skin assessments of the application sites at 30 min (30 min wear time 
assignment only), 60 min (1 hr), 12 hours and 24 hours post-dose will be summarized by 
treatment group using frequency tables. 
Descriptive summaries of actual values and changes from pre-dose to 10 min, 60 min (1 hr), 
120 min, 240 min (4 hr), and 720 minutes (12 hr) post-dose will be calculated for vital signs 
including heart rate, respiratory rate, systolic blood pressure, and diastolic blood pressure and 
presented by treatment group.   
Descriptive summaries of actual values and changes from pre-dose by treatment group will also 
be provided for the quantitative ECG parameters of rhythm, heart rate, PR interval, QRS interval, 
QT, QTcF, (Fridericia’s) corrections for heart rate. 
All safety data will be listed by subject and parameter, separate listings of all abnormal 
laboratory findings will be provided, and clinically significant abnormalities will be recorded as 
AEs.  
10.6 Analyses of Adhesion 
Adhesion scores will be summarized by time point and treatment group using frequency tables.  
Mean adhesion scored by time point and treatment group will also be provided.  Further details 
on the analysis of adhesion scores will be provided in the SAP. 
10.7 Analyses of Residual Drug 
Analyses may be performed to quantify the amount of drug remaining on the M207 patch system 
and the amount of drug recovered from the skin of the subject following removal of each of the 
patches.  In that case, a description of the disposition of the remaining drug will be presented.  
The results from analysis of residual zolmitriptan on the skin and the residual zolmitriptan on the 
used patches will provide a basis for the calculation of the total amount of drug delivered from 
each treatment. 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 43 of 69 
 
11 
ADMINISTRATIVE PROCEDURES 
11.1 Changes to the Protocol 
Any change or addition to the protocol requires a written protocol amendment initiated and 
approved by the sponsor, Zosano Pharma and the IRB/IEC and any applicable regulatory 
authority. 
Amendments of an administrative nature do not require formal protocol amendments or approval 
by the IRB/IEC, but the IRB/IEC must be informed in writing of such administrative changes.  
Examples include changes in the staff used to monitor the trial, editorial corrections and 
clarifications. 
11.2 Investigator Reporting Responsibilities to the Independent Ethics Committee and 
Other Agencies 
The Investigator must promptly report to the IRB/IEC all changes in the research activity and all 
unanticipated problems involving risk to human patients or others.  This includes all SAEs that 
have occurred at the study site and all study-related SAEs that have resulted in an expedited 
safety report to regulatory authorities (serious, unexpected SAEs possibly or probably related to 
study drug).  Concurrently, the Investigator must send documentation to the Sponsor of such 
IRB/IEC notification.  The Investigator must not make any changes in the research without 
IRB/IEC approval, except where necessary to eliminate apparent immediate hazards to human 
patient. 
11.3 Withdrawal and Study Termination 
Subjects will be informed that they are free to withdraw from the study at any time.  The 
Investigator, the Investigator in consultation with the Medical Monitor, or the Medical Monitor 
may exercise his/her medical judgment to terminate a participant’s participation in the study due 
to clinically significant changes in any clinical or laboratory parameter (See Section 4.3). 
Zosano Pharma reserves the right to terminate the study at any time.  All data normally collected 
at completion of the study must be collected either at the time of the subject’s early termination, 
or on or before the scheduled study close out. Subjects with ongoing AEs at termination will be 
followed until all significant changes have resolved or become medically stable. 
11.4 Monitoring 
The clinical site will permit trial-related monitoring, audits, IRB/IEC review and regulatory 
inspections by providing direct access to source data/documentation. 
The sponsor's representatives will monitor the study at all stages of study conduct from inception 
to completion in accordance with current GCPs/ICH-R and a study monitoring plan.  This 
monitoring will be in the form of site visits and other communication and will include review of 
original source documents and CRF.  The sponsor's monitor or representative will notify the 
principal Investigator prior to conducting any investigational site visit.  The frequency of these 
visits will depend upon the progress of the study, and will include monitoring to assess facilities, 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 44 of 69 
 
and required certifications, IRB/IEC notifications and approvals, equipment, recruiting, record-
keeping, protocol adherence, data collection, adverse event reporting and other factors. 
11.5 Retention of Documents 
The Investigator will retain all study documents for at least two years after the approval date for 
marketing the product or until 2 years after the investigational use of the study drug is 
discontinued.  The Investigator must obtain written permission from Zosano Pharma before 
destroying any study documents. 
11.6 Publicaton Policy 
All information concerning Zosano Pharma operations, patent applications, formulas, 
manufacturing processes, and basic scientific data provided by Zosano Pharma to the 
investigator and not previously publishes, are considered confidential and remain the sole 
property of Zosano Pharma. 
It is understood by the investigator that Zosano Pharma will use the information obtained in this 
clinical study in connection with M207, and therefore may disclose this information as required 
to other Zosano investigators, appropriate international regulatory agencies, or others.  In 
agreeing to participate in this study, the investigator understands that he/she has an obligation to 
provide complete test results and all data developed during this study to Zosano Pharma.  Zosano 
Pharma requires that permission to publish details of this study must be obtained in writing by 
Zosano as further detailed in the Clinical Study Agreement signed by the investigator and/or 
institution.  
11.7 Auditing Procedures 
Zosano Pharma or their agents and contractors may conduct audits of clinical research activities 
in accordance with applicable Standard Operating Procedures.  A regulatory authority may also 
wish to conduct an inspection (during the study or even after its completion).  If an inspection is 
requested by a regulatory authority, the investigator must inform Zosano Pharma immediately 
that this request has been made. 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 45 of 69 
 
12 
REFERENCES 
Assessing Adhesion with Transdermal Delivery Systems and Topical Patches for ANDAs, Draft 
Guidance for Industry.  US Department of Health and Human Services, Food and Drug 
Administration, Center for Drug Evaluation and Research (CDER). June 2016 
Dahlöf, C, Solomon G. The burden of migraine to the individual suffer: a review. Eur J Neurol. 
1998;5: 525–33. 
Guidance for Industry: Migraine: Developing Drugs for Acute Treatment. 2014 
Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 
1988;75:800-2. 
Lipton R, Scher A, Kolodner K, et al. Migraine in the United States: epidemiology and patterns 
of health care use. Neurol. 2002;58(6):885-94. 
Rapoport A, Ramadan N, Adelman J, et al. Optimizing the dose of zolmitriptan (Zomig, 
311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, 
dose range-finding study. Neurology. 1997;49(5):1210-18. 
Schoenen J, Caekebeke P, Louis, G, et al. An open study to investigate the absorption and 
tolerability of oral 311C90 and to obtain a preliminary indication of efficacy in migraine 
patients. Proceedings of the 10th Migraine Trust Symposium. New advances in headache 
research. 1994;vol. 4:11-2. 
Seaber E, Peck R, Smith D, et al. The absolute bioavailability and effect of food on the 
pharmacokinetics of zolmitriptan in healthy volunteers. Br J Clin Pharmacol. 1998 
Nov;46(5): 433–9.  
Visser W, Klein K, Cox R, et al. 311C90, a new central and peripherally acting 5-HT1D receptor 
agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose-range 
finding study. Neurology. 1996 Feb;46(2):522-6. 


 
Zosano Pharma Corporation 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 46 of 69 
 
13 
SCHEDULE OF ASSESSMENTS 
Assessment* 
Screening 
Visit** 
Admission/
baseline 
Dosing Visit*** 
End of 
Study/Early 
Termination 
 
Screening 
Day Prior 
to Each 
Dose 
Pre-
dose 
0 
mn 
2 
mn 
5 
mn 
10 
mn 
15 
mn 
20 
mn 
30 
mn 
45 
mn 
60 
mn 
90 
mn 
2 
hr 
4 
hr 
8 
hr 
12 
hr 
24 
hr 
Within 48 hours 
after completion 
of all procedures 
on final dosing 
day 
Informed consent 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical history/ 
demographics 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Concomitant 
medications 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Physical exam 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
X 
Serum pregnancy test 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
Urine dipstick 
pregnancy test 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Height 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weight 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
Confirm eligibility 
X 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical laboratory 
tests (CBC, 
hematology, UA) 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
Serology 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Urine Drug & Alcohol 
(breath) Testing 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Collect PK samples 
 
 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Study drug 
administration 
 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patch Adhesion Scale∞  
 
 
 
X 
 
 
 
 
 
X∞ 
 
X∞ 
 
 
 
 
 
 
 
Vital signs 
X 
 
X 
 
 
 
X 
 
 
 
 
X 
 
X 
X 
 
X 
 
X 
ECG 
X 
 
X 
 
 
 
 
X 
 
 
 
X 
 
 
 
X 
X 
 
X 


 
Zosano Pharma Corporation 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 47 of 69 
 
Assessment* 
Screening 
Visit** 
Admission/
baseline 
Dosing Visit*** 
End of 
Study/Early 
Termination 
 
Screening 
Day Prior 
to Each 
Dose 
Pre-
dose 
0 
mn 
2 
mn 
5 
mn 
10 
mn 
15 
mn 
20 
mn 
30 
mn 
45 
mn 
60 
mn 
90 
mn 
2 
hr 
4 
hr 
8 
hr 
12 
hr 
24 
hr 
Within 48 hours 
after completion 
of all procedures 
on final dosing 
day 
Remove and retain 
(freeze) patches (at 
30 min or 60 min 
depending on 
assignment) 
 
 
 
 
 
 
 
 
 
X 
 
X 
 
 
 
 
 
 
 
Investigator skin 
assessment of the 
application sites● 
 
 
X 
 
 
 
 
 
 
 X● 
 
X● 
 
 
 
 
X 
X 
 
X 
Swabbing**** 
 
 
 
 
 
 
 
 
 
X 
 
X 
 
 
 
 
 
 
 
Record Adverse 
events 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* When multiple procedures are scheduled for the same time point, PK samples will be taken at the protocol assigned time point within plus or minus 1 minute of the 
specified time points for the first hour and within plus or minus 5 minutes of the specified time points after one hour.  The other measurements (i.e., vital signs, ECG, 
skin assessments) will be taken before or after the protocol-specified time point within an interval of plus or minus 5 minutes. 
** Screening Visit – Up to 30 days prior to first admission/baseline visit. 
*** The washout period following each dose must be a minimum of 48 hours until the next dose is administered. 
∞   Patch Adhesion Scale – Only the 60 min wear time treatment assignment will have the scale completed at both 30 and 60 min. 
● Investigator skin assessment – The 30 min assessment is only applicable to the 30 min wear time treatment assignments and the 60 min skin assessment is only 
applicable to the 60 min wear time group. 
**** Swabbing of both patch sites will occur when patches are removed at either 30 or 60 min depending on the wear time treatment assignment.   
 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 48 of 69 
 
APPENDIX 1: 
M207 PATCH ADMINISTRATION 
 
TABLE OF CONTENTS 
I. 
INTRODUCTION 
II. 
GENERAL DESCRIPTION 
1. The Patch 
2. The Applicator 
3. Storage 
III. 
PRECAUTIONS AND OTHER NOTES  
IV. 
INSTRUCTIONS FOR USE 
1. Before You Apply the Patch 
2. Opening the Packaging 
3. Attaching the Patch Ring to the Applicator and Applying the Patch 
4. After Applying the Patch 
5. Removing the Patch 
 
 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 49 of 69 
 
I. 
INTRODUCTION 
The M07 patches and a specially designed applicator are made by Zosano Pharma.  This User’s 
Guide provides instructions for the clinical staff on how to apply patches to subjects.  The 
patches look like round adhesive Band-Aids and have study drug on tiny metal points on one 
side.  Patches are applied to the subject’s skin using a spring-loaded applicator specially designed 
for these patches.  Each patch is used only once.  The applicator can be reused. 
II. 
GENERAL DESCRIPTION 
The M207 intracutaneous microneedle system has two parts: a patch attached to a plastic 
supporting ring, and an applicator. 
1. The Patch: The patch comes attached to a plastic supporting ring that allows you to attach it 
to the applicator.  When you apply the patch to the skin, the patch stays on the skin and the 
plastic ring stays on the applicator and is later thrown away. 
 
Top 
Bottom 
 
There is study drug on the shiny metal on the sticky side of the patch.  You can touch the 
supporting plastic ring, but do not touch the sticky side of the adhesive patch or the shiny metal 
piece with your fingers.  Touching this may damage the patch. 
Patch 
backing 
Plastic support ring 
Shiny metal 
surface 
Plastic 
support ring 
Adhesive 
Patch with 
drug 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 50 of 69 
 
2. The Applicators 
Applicator 0.26J 
 
 
Use the applicator to apply the patch for treatments A-C to the skin.  Hold the applicator in 
your hand to apply the patch.  The patch cannot be applied without the applicator.  The ring and 
patch attach to the bottom of the applicator.  The applicator cap is twisted to unlock the 
applicator.  When the applicator is pressed against the skin, a plunger pushes the patch out of the 
support ring and applies it to the skin. 
3. Storage of Supplies (patches and applicators): 
Room temperature storage: Store the patches in their cups at room temperature.  Store the 
applicator at room temperature in its box between uses. 
III. 
PRECAUTIONS AND OTHER NOTES 
Lotions, Ointments, or Powders: Ensure no lotions, ointments, or powders have been 
applied to the patch application sites immediately before or after applying the patch. 
Wash Hands: Always wash your hands before applying a patch. 
 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 51 of 69 
 
IV. INSTRUCTIONS FOR USE 
1. Before You Apply the Patch 
• Check the skin at the upper arm or thigh to be sure that it is not irritated from rash, 
inflammation, redness, or other skin problems such as cuts or open wounds.  In addition, 
the application area must be free of tatoos, scars, birthmarks, and/or any skin 
abnormalities. 
• Clean the the skin area (upper arm or thigh) where the patches will be applied with an 
alcohol wipe.  Only wipe with alcohol prior to the first patch application for each dose. 
2. Opening the Cup Containing the Patch and Plastic Ring 
Patch and Ring in Package 
 
 
• Each patch is individually sealed in its own protective outer cup.  
• DO NOT USE the patch if its cup has a hole in it, has already been torn open, or is 
otherwise damaged. 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 52 of 69 
 
• With the tab pointing towards you, to open the cup, lay the cup flat with printed side up.  
Using the notches provided, slowly peel back the top layer of the cup to open with “This 
side up” facing up.  If the cup is difficult to open, you can use scissors to cut along the 
dotted line. 
 
 
 
• Leave the patch on the bottom side of the cup.  You can touch the white plastic patch ring 
with your fingers.  However, do not touch the patch or shiny metal surface of the patch 
with your fingers.  This may damage or contaminate the patch. If you accidentally touch 
the shiny metal surface with your finger, return the patch to the original cup, write the 
date on the cup, and start over with a new patch. 
 
 
 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 53 of 69 
 
3. Attaching the Patch Ring to the Applicator, and Applying the Patch to the Skin 
(see Figure 1) 
 
1. 
Prepare the patch and applicator 
o 
Open the applicator box and remove the applicator from its box 
o 
Ensure the applicator is set to ‘1’.  The applicator is ready to attach a patch 
when in the number ‘1’ position.  If the number ‘2’ is showing in the window, 
change it to ‘1’ by depressing the applicator onto your palm or other soft 
surface until it activates. 
o 
Ensure the patch is sitting shiny metal side down.  If not, gently pick up the 
patch ring assembly by touching only the plastic support ring and flip it over.  
The shiny metal side should now be face down. 
2. Attach the patch and ring to the applicator by placing the applicator directly on top of 
the patch ring and push down gently until the patch clicks into place.  You will likely 
hear or feel a “click.” The patch is now attached to the applicator. 
3. Holding the bottom half of the applicator with one hand, unlock the applicator by 
twisting the top half of the applicator clockwise until it clicks into the “2” position. 
The patch and applicator are now ready for application. 
4. Ensure the number shows ‘2’ in the window, indicating the applicator is unlocked.  If 
not, go back to step 4 to change it from ‘1’ to ‘2’. 
5. Place the applicator on the skin and push the applicator against the skin. 
6. When you have pushed against the skin hard enough, you will hear the plunger push the 
patch from the ring onto the skin.  Continue to hold the applicator down against the skin 
for 3 seconds.  The patch is now applied and the medicine is now being delivered through 
the patch.  You may now remove the applicator.  You will see the patch sticking to the 
skin.  The empty plastic ring will still be attached to the applicator. 
7. If edges of the patch are lifted or curled, lightly press down WITH THE FLAT OF 
YOUR PALM to make the patch stick to the skin better. 
8. DO NOT USE YOUR FINGERTIPS to press the edges of the patch because your 
fingertips may push one side down but pull the other side loose. 
9. With your forefinger and thumb, remove the ring from the bottom of the applicator by 
pulling it out.  You may discard the ring in the rubbish bin. 
10. Leave the patches on the subject’s skin for the duration assigned in accordance with the 
protocol treatment assignment (30 minutes or 60 minutes). 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 54 of 69 
 
Figure 1: 
M207 Patch Application 
 
 
 
 
 
1. Snap patch-ring assembly onto 
applicator 
 
 
 
2. Twist applicator cap clockwise from  
Position 1 to Position 2 to unlock for 
patch application 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 55 of 69 
 
 
 
 
3. Place applicator against cleaned area 
and press applicator downward to apply 
patch to skin until you hear a click then 
HOLD for 3 seconds.  Patch is applied. 
Ring assembly remains attached to the 
applicator 
 
 
 
4. Remove the outer ring in order to load 
and apply the second patch. 
 
 
 
5. Repeat all of the above steps to apply 
second patch next to the first patch 
 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 56 of 69 
 
4. After Applying the Patch 
Leave the patches on the subject’s skin for the duration assigned in accordance with the protocol. 
Before applying the second patch, remove the used plastic support ring from the applicator and 
discard it.  Use your finger to pull the used patch ring off the applicator.  Throw away the patch 
ring. 
 
 
5. Removing the Patch 
After the appropriate assigned time of patch application, peel the edge of the patch back and 
remove the patches from the subject’s skin as you would remove a Band-Aid.  Refer to 
Appendix 3 for handling and processing of used patches, storage, and return instructions. 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 57 of 69 
 
APPENDIX 2: 
ZOLMITRIPTAN PK SAMPLE HANDLING 
1. 
Plasma Zolmitriptan Sample Collection 
Approximately 4 ml of blood will be collected into a labeled K2 EDTA blood collection tubes at 
each pharmacokinetic time point as specified in the the schedule of events.  The actual date and 
time of blood collection will be recorded for each subject.    
The blood samples will be maintained in a chilled ice bath prior to centrifuging.  The samples 
will be centrifuged for 10 minutes at 4○C at 2000 x g and the aliquots will be placed in the 
freezer within 60 minutes of sample collection.  The plasma supernatant will be transferred to 
polypropylene tubes and labeled identically to the original sample container.  Two aliquots will 
be prepared.  Plasma will be aliquoted into a separate LDPE containers labeled (at minimum) 
with the study number, subject’s identification number, date and time of collection, and analyte 
(zolmitriptan).  Aliquot 1 will contain 1 mL of plasma, and Aliquot 2 will contain the rest of the 
plasma (approximately 1 mL). After processing, the tubes will be sealed and the plasma will be 
frozen in an upright position (to avoid frozen plasma in the caps) and stored in a -80 °C 
(+/- 10 °C) freezer in an upright position until shipped for analysis.  The plasma samples will be 
shipped to the bioanalytical laboratory on dry ice.   
Each sample will be labeled or barcoded (at minimum) with the study number, subject 
identification number, actual date and time of collection, analyte (zolmitripan). 
2. 
Plasma Zolmitriptan Sample Shipment 
Securely pack the frozen samples in Styrofoam freezer boxes with sufficient dry ice to ensure the 
samples remain frozen for at least 72 hours.  Samples will be transported to the bioanalytical 
facility in at least two separate shipments, with each set of aliquots in separate shipments.  Once 
the bioanalytical laboratory confirms receipt of the first shipment, the second set of aliquots 
may be sent upon approval by Zosano.  The shipping container will include TempTale 
temperature monitoring device provided by World Courier.  


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 58 of 69 
 
APPENDIX 3: 
HANDLING AND PROCESSING OF USED PATCHES AND SKIN 
SWABS  
Delivery performance of M207 patches is determined by drug residual analysis.  The amounts of 
zolmitriptan left on the microneedle array and skin surface after each application are compared 
against the original coated amount on the array, allowing total amount delivered or delivery 
efficiency to be determined by mass balance.  This Appendix 3 provides detailed procedures for 
used patch removal and subsequent swabbing of the treated skin surface.  The collected used 
patches and skin swabs (in swab buffer) will be shipped to the site where plasma samples are 
analyzed.  
MATERIALS:  
A. Content of Used Patches and Skin Swabbing Kits 
Figure 1 outlines the materials provided by Zosano to perform the used patch collection and skin 
swabbing procedures.  The materials for both procedures will be combined into one kit (for each 
dosing period) and designated as the Used Patch/Skin Swab Kit.  Each kit contains materials 
(Table 1) to collect from one dosed patient: 2 used patches and two skin swabbing for each patch.   
 
 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 59 of 69 
 
PROCEDURE: 
USED PATCH REMOVAL PROCEDURE FROM SKIN AND PROCESSING 
Refer to Figure 1 (above) for material identification and Figure 2 (below) for used patch removal 
procedure.  Note the following procedural highlights:  
1. Do not touch or contaminate the patch-treated skin sites after patch removal.   
2. Since each patient has two patches applied, remove one patch at a time and note the skin 
area where the patch was removed for subsequent skin swabbing in Section B.  
3. Try to perform used patch removal and skin swabbing, for the first and second patches, 
within 5 minutes of the removal of the first used patch. 
 
A minimum of 80 kits will be provided by Zosano and of the 80, 8 (10%) kits are allotted for 
backups and 72 are allotted for 24 subjects with 3 treatments.  Once the used patch collection and 
skin swabbing are completed for all subjects, there should be in total 144 used patch vials and 
144 swab buffer vials to be processed and shipped to Syneos Health.  


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 60 of 69 
 
Table 1. 
Tally/Labeling of Materials Included in each Used Patch/Skin Swab Kit 
Item # 
Description 
Quantity 
Labeling 
1* 
Orange-cap cryovial with 1-mL swab buffer 
2 
#1 to 144 (sequentially) with 
“1-mL Swab Buffer” 
2** 
Swab buffer vial with 1 dry swab 
2 
**For Items # 2 and 4 include 
at least the following: 
- Subject ID 
- Patch location (upper arm or 
thigh and number or side 
(e.g., 1 and 2, or left and right)  
- Sample collection date and 
time 
- Protocol number  
3 
Sterile forceps, individually packaged 
2 
4** 
Used patch collection vial 
2 
5 
Ziploc bag for Item 4 
2 
6 
Vial with 4 dry swabs 
1 
7 
Purple-top 50-mL tube 
2 
8** 
White tub with yellow lid to contain Items 1-7 
1 
*This orange-cap cryovial containing buffer will be stored in refrigeration at approximately 0-4°C and 
removed several hours before swabbing. 
 
Labeling: *Item #1 will be numbered from 1 to 144 by Zosano.  **Items # 2, 4 and 8 will need 
to be labeled prior to use with a minimum of the following: Subject ID, patches location (upper 
arm or thigh), and numbering or position (e.g., site 1 or 2 or left/right), sample collection date 
and time, and protocol number. 
B. Skin Swabbing After Each Used Patch Removal 
Refer to Figure 1 for material identification and Figure 3 for skin swabbing procedure. 
For each separate patch, the patch-treated skin surface is swabbed using three polyurethane 
swabs: 1 wetted and 2 dry.  The first swab is soaked in 1.0-mL of  0.05% Tween 20 (in phosphate 
buffer saline).  The 0.05% Tween 20 in phosphate buffer saline is also referred to as “swab 
buffer” and shown in Figure 1, Item 1.  The wetted swab is applied over the skin site by rolling 
the swab with slight pressure in several directions (e.g., left to right and up and down) and around 
the periphery of the treatment site.  Two additional swabs, dry, are applied sequentially over the 
wetted skin site using the same rolling motions to absorb all residual buffer.  Make sure to absorb 
all residual buffer on the skin since this is the medium used to capture the residual zolmitriptan 
from the skin.  Once used, all three swabs are placed in the swab buffer vial and sent Syneos 
Health for zolmitriptan analysis. 
Note the following procedural highlights: 
1) Cryovials with swab buffer: 1-mL of the swab buffer aliquot is contained in each orange-cap 
cryovial (Item #1) and 144 will be sent from Zosano and should be stored at 0-4°C prior to use.  
Two cryovials (containing buffer) are allotted for each of the two used patches and should be 
removed from refrigeration and placed with Kit several hours before swabbing.  At least 1 hour 
before swabbing, pour the content of one cryovial into one swab buffer vial with dry swab 
(Item # 2) and repeat for the other set.  Place both swab buffer vials into the Kit tub to keep them 
slightly upright as shown. 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 61 of 69 
 
2) Start skin swabbing procedure immediately after patch removal. 
3) Try to complete used patch removal and skin swabbing, for first and second patch, within 
5 minutes of the removal of the first used patch. 
4) Wetted swab should not be dripping with excess buffer when pulled out for swabbing. Keep 
all swabs clean until used. 
5) Apply the wetted swab over the treated skin site by rolling (back-and-forth) the swab with 
slight pressure in several directions (e.g., left to right and up and down) and around the periphery 
of the treatment site.  Once swabbing is done, place the wetted swab back into the swab buffer 
vial. 
6) Apply two additional swabs (dry), one at a time, over the wetted skin site using the same 
rolling motions to absorb all residual buffer on the skin. Once swabbing is done, place both 
swabs into the same swab buffer vial. 
 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 62 of 69 
 
C. Packing of Used Patches and Skin Swabs  
Refer to Figure 4 for packing illustration.  Use the Kit tub to pack the used patch vials (2) and 
swab buffer vials (2) collected from each dosed patient.  Pack all tubs in dry ice for shipping and 
ship upon authorization from Zosano Pharma. 
 
 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 63 of 69 
 
APPENDIX 4: 
SHIPPING PROCEDURES FOR UNUSED PATCHES 
AND NEW APPLICATORS 
1. Unused Patch Collection and Shipment 
Collection: All unused systems should be stored in their original cups and shipping box, at room 
temperature until shipment to Zosano Pharma. 
Shipment: All unused systems should be combined into one shipment and shipped at room 
temperature - upon authorization from Zosano Pharma. 
Shipments should be made via World Courier using the Zosano Pharma World Courier 
Account number 13334. 
All returned packages should contain the statement: “For research purposes only.  Not for human 
use.” 
Complete the Product Return Form (provided by Sponsor) and include with each return 
shipment: 
• Insert 1 copy in a separate plastic bag in the sample container box which will act as a 
packing slip. 
• Keep 1 copy in the Regulatory binder  
• Fax or email one copy to Zosano Pharma, Lu Liu (LuLiu@zosanopharma.com) and 
Whitney Halladay (whalladay@zosanopharma.com), Fax: +1-510-952-4632, 
Phone: +1-510-745-1289 
 
Unused Patch shipments to Zosano Pharma should be addressed to: 
Zosano Pharma 
ATTN: Lu Liu 
Senior Director, Manufacturing and Supply Chain 
34790 Ardentech Court 
Fremont, CA 94555 USA 
Phone: + 1 510-745-1289 
Fax: +1-510-952-4632 
 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 64 of 69 
 
2. New Applicator Collection and Shipment 
Collection: At the completion of the study, place the used applicators back into the original 
applicator box or equivalent.  Place the applicator boxes into a Ziploc bag and label bag with 
“Used Applicators.”  Place all unused applicators into another Ziploc bag and label bag with 
“Unused Applicators.”  Store used and unused applicators at room temperature until shipment to 
Zosano Pharma.  All samples should be shipped in one shipment. 
Shipment: Securely pack the bags of used and/or unused applicators into suitable boxes 
containing shipping materials (e.g., Styrofoam “popcorn” or bubble-wrap).  Both used and 
unused applicators may be shipped back to Zosano Pharma at ambient temperature. 
Shipments should be made via World Courier using the Zosano Pharma World Courier 
Account 13334.  
All returned packages should contain the statement: “For research purposes only.  Not for human 
use.” 
Complete the Product Return Form (provided by Sponsor) and include with each return 
shipment: 
• Keep 1 copy in the Regulatory binder 
• Place another copy of the Form in a Ziploc back and place the Ziploc bag inside the 
shipping container; this copy will be used as the packing slip for the shipment.   
• Fax or email one copy to Zosano Pharma, Lu Liu (LuLiu@zosanopharma.com) and 
Whitney Halladay (whalladay@zosonopharma.com), Fax: +1-510-952-4632, 
Phone +1-510-745-1289 
 
Applicator shipments to Zosano Pharma Corporation: 
Zosano Pharma Corporation 
ATTN: Lu Liu 
Senior Director, Manufacturing and Supply Chain 
34790 Ardentech Court 
Fremont, CA 94555 USA 
Phone: +1510-745-1289 
Fax: +1-510-952-4632 
 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 65 of 69 
 
APPENDIX 5: 
DECLARATION OF HELSINKI 
 
WORLD MEDICAL ASSOCIATION DECLARATION 
OF HELSINKI Ethical Principles for Medical Research 
Involving Human Subjects 
 
Adopted by the 18th WMA General 
Assembly 
Helsinki, Finland, June 1964 and 
amended by the 
29th WMA General Assembly, Tokyo, Japan, 
October 1975 
35th WMA General Assembly, Venice, Italy, 
October 1983 
41st WMA General Assembly, Hong Kong, 
September 1989 
48th WMA General Assembly, Somerset West, Republic of South 
Africa, October 
1996and the52nd WMA General Assembly, Edinburgh, Scotland, 
October 2000 
 
INTRODUCTION 
The World Medical Association has developed the Declaration of Helsinki as a statement of 
ethical principles to provide guidance to physicians and other subjects in medical research 
involving human subjects.  Medical research involving human subjects include research on 
identifiable human material or identifiable data. 
It is the duty of the physician to promote and safeguard the health of the people.  The physician’s 
knowledge and conscience are dedicated to the fulfillment of this duty. 
The Declaration of Geneva of the World Medical Association binds the physician with the words, 
“The health of my patient will be my first consideration,” and the International Code of Medical 
Ethics declares that, “A physician shall act only in the patient’s interest when providing medical 
care which might have the effect of weakening the physical and mental condition of the patient.” 
Medical progress is based on research that ultimately must rest in part on experimentation 
involving human subjects. 
In medical research on human subjects, considerations related to the well being of the human 
subjects should take precedence over the interests of science and society. 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 66 of 69 
 
The primary purpose of medical research involving human subjects is to improve prophylactic, 
diagnostic and therapeutic procedures and the understanding of the etiology and pathogenesis of 
disease.  Even the best-proven prophylactic, diagnostic, and therapeutic methods must 
continuously be challenged through research for their effectiveness, efficiency, accessibility and 
quality. 
In current medical practice and medical research, most prophylactic, diagnostic and therapeutic 
procedures involve risks and burdens. 
Medical research is subject to ethical standards that promote respect for all human beings and 
protect their health and rights.  Some research populations are vulnerable and need special 
protection.  The particular needs of the economically and medically disadvantaged must be 
recognized.  Special attention is also required for those who cannot give or refuse consent for 
themselves, for those who may be subject to giving consent under duress, for those who will not 
benefit personally from the research and for those for whom the research is combined with care. 
Research Investigators should be aware of the ethical, legal and regulatory requirements for 
research on human subjects in their own countries as well as applicable international 
requirements.  No national ethical, legal or regulatory requirement should be allowed to reduce or 
eliminate any of the protections for human subjects set forth in this Declaration. 
BASIC PRINCIPLES FOR ALL MEDICAL RESEARCH 
It is the duty of the physician in medical research to protect the life, health, privacy, and dignity 
of the human subjects. 
Medical research involving human subjects must conform to generally accepted scientific 
principles, be based on a thorough knowledge of the scientific literature, other relevant sources of 
information, and on adequate laboratory and, where appropriate, animal experimentation. 
Appropriate caution must be exercised in the conduct of research that may affect the 
environment, and the welfare of animals used for research must be respected. 
The design and performance of each experimental procedure involving human subjects should be 
dearly formulated in an experimental protocol.  This protocol should be submitted for 
consideration, comment, guidance, and where appropriate, approval to a specially appointed 
ethical review committee, which must be independent of the Investigator, the sponsor or any 
other kind of undue influence.  This independent committee should be in conformity with the 
laws and regulations of the county in which the research experiment is performed.  The 
committee has the right to monitor ongoing trials.  The researcher has the obligation to provide 
monitoring information to the committee, especially any serious adverse events.  The researcher 
should also submit to the committee, for review, information regarding funding, sponsors, 
institutional affiliations, other potential conflicts of interest and incentives for subjects. 
The research protocol should always contain a statement of the ethical considerations involved 
and should indicate that there is compliance with the principles enunciated in this Declaration. 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 67 of 69 
 
Medical research involving human subjects should be conducted only by scientifically qualified 
persons and under the supervision of a clinically competent medical person.  The responsibility 
for the human subject must always rest with a medically qualified person and never rest on the 
subject of the research, even thought the subject has given consent. 
Every medical research project involving human subjects should be preceded by careful 
assessment of predictable risks and burdens in comparison with foreseeable benefits to the 
subject or to others.  This does not preclude the participation of healthy volunteers in medical 
research.  The design of all studies should be publicly available. 
Physicians should abstain from engaging in research projects involving human subjects unless 
they are confident that the risks involved have been adequately assessed and can be satisfactorily 
managed.  Physicians should cease any investigation if the risks are found to outweigh the 
potential benefit or if there is conclusive proof of positive and beneficial results. 
Medical research involving human subjects should only be conducted if the importance of the 
objective outweighs the inherent risks and burdens to the subject.  This is especially important 
when the human subjects are healthy volunteers. 
Medical research is only justified if there is a reasonable likelihood that the populations in which 
the research is carried out stand to benefit from the results of the research. 
The subjects must be volunteers and informed subjects in the research project. 
The right of research subjects to safeguard their integrity must always be respected.  Every 
precaution should be taken to respect the privacy of the subject, the confidentiality of the 
patient’s information and to minimize the impact of the study on the subject’s physical and 
mental integrity and on the personality of the subject. 
In any research on human beings, each potential subject must be adequately informed to the 
aims, methods, sources of funding, any possible conflicts of interest, institutional affiliations of 
the researcher, the anticipated benefits and potential risks of the study and the discomfort it may 
entail.  The subject should be informed of the right to abstain from participation in the study or to 
withdraw consent to participate at any time without reprisal.  After ensuring that the subject has 
understood the information, the physician should then obtain the subject’s freely given informed 
consent, preferably in writing.  If consent cannot be obtained in writing, non-written consent 
must be formally documented and witnessed. 
When obtaining informed consent for the research project the physician should be particularly 
cautious if the subject is in a dependent relationship with the physician or may consent under 
duress.  In that case the informed consent should be obtained by a well-informed physician who 
is not engaged in the investigation and who is completely independent of this relationship. 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 68 of 69 
 
For research subject who is legally incompetent, physically or mentally incapable of giving 
consent or is a legally incompetent minor, the Investigator must obtain informed consent from 
the legally authorized representative in accordance with applicable law.  These groups should not 
be included in research unless the research is necessary to promote the health of the population 
represented and this research cannot instead be performed on legally competent persons. 
When a subject deemed legally incompetent, such as a minor child, is able to give assent to 
decisions about participation in research, the Investigator must obtain that assent in addition to 
the consent of the legally authorized representative. 
Research on individuals from whom it is not possible to obtain consent, including proxy or 
advance consent, should be done only if the physical/mental condition that prevents obtaining 
informed consent is a necessary characteristic of the research population.  The specific reasons 
for involving research subjects with a condition that renders them unable to give informed 
consent should be stated in the experimental protocol for consideration and approval of the 
review committee.  The protocol should state that consent to remain in the research should be 
obtained as soon as possible from the individual or a legally authorized surrogate. 
Both authors and publishers have ethical obligations. In publication of the results of research, the 
Investigators are obliged to preserve the accuracy of the results.  Negative as well as positive 
results should be published or otherwise publicly available.  Sources of funding, institutional 
affiliations and any possible conflicts of interest should be declared in the publication.  Reports 
of experimentation not in accordance with the principles laid down in this Declaration should not 
be accepted for publication. 
ADDITIONAL PRINCIPLES FOR MEDICAL RESEARCH COMBINED WITH 
MEDICAL CARE. 
The physician may combine medical research with medical care, only to the extent that the 
research is justified by its potential prophylactic, diagnostic or therapeutic value.  When medical 
research is combined with medical care, additional standards apply to protect the patients who 
are research subjects. 
The benefits, risks, burdens and effectiveness of a new method should be tested against those of 
the best current prophylactic, diagnostic and therapeutic methods.  This does not exclude the use 
of placebo, or no treatment, in studies where no proven prophylactic, diagnostic or therapeutic 
method exists. 
At the conclusion of the study, every patient entered into the study should be assured of access to 
the best-proven prophylactic, diagnostic and therapeutic methods identified by the study. 
The physician should fully inform the patient which aspects of the care are related to the 
research.  The refusal of a patient to participate in a study must never interfere with the patient-
physician relationship.  In the treatment of a patient, where proven prophylactic, diagnostic and 
therapeutic methods do not exist or have been ineffective, the physician, with informed consent 
from the patient, must be free to use unproven or new prophylactic, diagnostic and therapeutic 
measures, if in the physician’s judgment it offers hope of saving life, re-establishing health or 


 
Zosano Pharma Corporation 
 
Protocol No. CP-2018-002v1 
 
12 September 2018 
Confidential 
Page 69 of 69 
 
alleviating suffering.  Where possible, these measures should be made the object of research, 
designed to evaluate their safety and efficacy. In all cases, new information should be recorded 
and, where appropriate, published.  The other relevant guidelines of this Declaration should be 
followed. 

SAP_001.pdf: 
CP-2018-002 SAP Version: Draft DD MMM YYYY 
  Confidential 
 Page 1 of 82 
Statistical Analysis Plan 
Protocol No.: CP-2018-002 
“A randomized open-label four-way crossover study to compare the 
pharmacokinetics, safety, and tolerability of M207 3.8 mg (administered as two 1.9 
mg patches) at two different application locations (upper arm and thigh) for 30 
minutes with intranasal zolmitriptan 2.5 mg and 1 hour wear time (upper arm) in 
healthy volunteers” 
Date of Protocol: 12 Sep 18 
Protocol Version Number: Draft 
Sponsor 
Zosano Pharma Corporation 
34790 Ardentech Court, 
Fremont, CA 94555, 
United States 
Prepared by 
   Fax# +91 -79 – 66135602 
Property of Cliantha Research Limited - Confidentiality Statement 
This SAP is the confidential and proprietary information of the Cliantha Research Limited and 
Zosano Pharma Corporation. It was developed for Zosano Pharma Corporation, by Cliantha 
Research Limited and should not be disclosed to a third party, with the exception of regulatory 
agencies and study audit personnel. Reproduction, modification or adaptation, in part or in total, is 
strictly forbidden without prior written approval by Cliantha Research Limited. 
Cliantha Research Limited 
Sigma-1 Corporate 
B/H Rajpath Club 
Opposite Mann Party Plot 
Off. S.G. Highway, Bodakdev 
Ahmedabad-380054 
Gujarat, India 
Tel# +91 -79 – 66135628 




CP-2018-002 Version: Draft DD MMM YYYY 
  Confidential 
 Page 3 of 82  
LIST OF ABBREVIATIONS 
Abbreviation 
Definition 
AE 
Adverse event 
ALT 
Alanine aminotransferase 
AP 
Alkaline phosphatase 
AST 
Aspartate aminotransferase 
AUC 
Area under the curve 
AUC30min 
Area under the curve from minute 0 to minute 30 
AUC60min 
Area under the curve from minute 0 to minute 60 
AUC120min 
Area under the curve from minute 0 to minute 120 
AUCt
Area under the curve from 0 hours to the last measureable 
concentration 
AUCinf 
Area under the curve extrapolated to infinity 
BMI 
Body Mass Index 
BP 
Blood pressure 
BSAP 
Bone specific alkaline phosphate 
C 
Celsius 
CBC 
Complete blood count 
Ct 
Concentration at time t 
CFR 
Code of Federal Regulations 
CM 
Concomitant medication 
cm2 
Centimeter squared 
Cmax 
Maximum observed plasma concentrations 
CPK 
Creatinine phosphokinase 
CRF 
Case report form 
dL 
Deciliter 
ECG 
Electrocardiogram 
EDTA 
Ethylenediaminetetraacetic acid 
F 
Fahrenheit 
GCP 
Good Clinical Practice 
GGT 
gamma glutamyl transpeptidase 
H 
Hour 
HCl 
Hydrochloride 
HRT 
Hormone replacement therapy 
ICF 
Informed consent form 
ICH 
International Conference on Harmonisation 
IEC 
Independent Ethics Committee 
IM 
Intramuscular 
IRB 
Institutional Review Board 
IV 
Intravenous 
J 
Joules 


   
 
 
 
 
 
 
 
CP-2018-002 Version: Draft DD MMM YYYY              
  Confidential         
 
             Page 4 of 82                                                                   
Abbreviation 
Definition 
k 
Apparent elimination rate constant 
kg 
Kilogram 
KIU 
Kilo international units 
µg 
Microgram 
L 
Liter 
LDH 
Lactate dehydrogenase 
LOCF 
Last observation carry forward 
µm 
Micrometer 
mL 
Milliliters 
mmol 
millimole(s) 
NSAID 
Nonsteroidal anti-inflammatory drug 
OCT 
Optical Coherence Tomography 
PD 
Pharmacodynamics 
PE 
Physical examination 
PK 
Pharmacokinetics 
PPI 
Proton pump inhibitors 
PRSPB 
Bruising 
PTH 
Parathyroid hormone  
SAE 
Serious adverse event 
SC 
Subcutaneous 
SD 
Standard deviation 
t½ 
Apparent half life 
TEAE 
Treatment-emergent adverse event 
TGA 
Therapeutic Goods Administration 
Tmax 
Time to maximum concentration 
ZP 
Zosano Pharma 
M207 
Zosano intracutaneous microneedle system containing 
zolmitriptan 
 


   
 
 
 
 
 
 
 
CP-2018-002 Version: Draft DD MMM YYYY              
  Confidential         
 
             Page 5 of 82                                                                   
TABLE OF CONTENTS 
 
1.0 Introduction ................................................................................................................. 9 
2.0 Study Title.................................................................................................................... 9 
3.0 Study Objectives.......................................................................................................... 9 
4.0 Study Description ........................................................................................................ 9 
4.1 Randomization and Blinding .................................................................................................... 9 
4.2 Pharmacokinetic Variables ..................................................................................................... 10 
4.3 Safety Assessment .................................................................................................................... 10 
4.4 Sample Size .............................................................................................................................. 10 
4.5 Study Design, Treatment and Plan ........................................................................................ 11 
4.6 Subject Population .................................................................................................................. 12 
4.7 Number of Subjects ................................................................................................................. 12 
4.8 Study Duration ........................................................................................................................ 12 
4.9 Withdrawal/Discontinuation Criteria ................................................................................... 12 
5.0 Endpoints ................................................................................................................... 13 
5.1 Safety and Tolerability ............................................................................................................ 13 
5.2 Safety Overview ....................................................................................................................... 13 
6.0 Study Populations (Definition of Populations for Analysis) ................................. 13 
6.1 Pharmacokinetic Population .................................................................................................. 13 
6.2 Safety Population ..................................................................................................................... 14 
7.0 Incomplete and Missing Data .................................................................................. 14 
8.0 Study Subjects and Conduct .................................................................................... 14 
9.0 Demographic Characteristics .................................................................................. 14 
10.0 Prior and Concomitant Medications ....................................................................... 15 
11.0 Pharmacokinetic Analysis ........................................................................................ 15 
12.0 Assessment Details .................................................................................................... 17 
13.0 Subject Disposition.................................................................................................... 20 
14.0 Protocol Deviations/Violation .................................................................................. 20 
15.0 Handling of data from visit ...................................................................................... 20 
16.0 Safety Analyses .......................................................................................................... 20 
16.1 Adverse Events ....................................................................................................................... 20 
16.1.1 Missing and Partial AE Onset Date/Time ......................................................................... 21 
16.2 Vital Signs ............................................................................................................................... 22 


   
 
 
 
 
 
 
 
CP-2018-002 Version: Draft DD MMM YYYY              
  Confidential         
 
             Page 6 of 82                                                                   
16.3 ECG ......................................................................................................................................... 22 
16.4 Investigator Skin Assessments .............................................................................................. 22 
16.5 Clinical Laboratory Evaluations .......................................................................................... 22 
16.6 Physical examination ............................................................................................................. 22 
17.0 Medical history .......................................................................................................... 22 
18.0 Patch Adhesion .......................................................................................................... 22 
19.0 Residual Drug Analyses ............................................................................................ 22 
20.0 Extent of Exposure .................................................................................................... 23 
Mock Tables ................................................................................................................................... 24 
Summary Table 12.1: Extent of Exposure for all Dosed Subjects ............................................. 25 
Summary Table 14.1.1: Summary of Subject Disposition.......................................................... 26 
Summary Table 14.1.2.1: Summary of Demographics ............................................................... 27 
Summary Table 14.1.2.2. Summary of Mean Demographic Data (± SD) ................................. 29 
Summary Table 14.2.1.1: Descriptive Statistics of Zolmitriptan Pharmacokinetic Parameters30 
Summary Table 14.2.1.2: Descriptive statistics of Zolmitriptan concentration (unit) data .... 33 
Summary Table 14.2.2.1: Summary of Statistical Analysis for M207 patches compared to 
Intranasal zolmitriptan ........................................................................................................... 35 
Summary Table 14.3.1.1: Overview of Adverse Event ............................................................... 37 
Summary Table 14.3.1.2: Incidence of AE by SOC and PT by Treatment Group .................. 38 
Summary Table 14.3.1.3: Summary of Treatment Emergent Adverse Events by SOC, PT 
and Severity .............................................................................................................................. 39 
Summary Table 14.3.1.4: Summary of Treatment Emergent Adverse Events by SOC, PT 
and Causality ........................................................................................................................... 40 
Listing 1: Listing of Adhesion Score for Test Treatment (A) - M207 Arm 30 minutes41 
Listing 2: Listing of Adhesion Score for Test Treatment (B) - M207 Thigh 30 
minutes ....................................................................................................................... 42 
Listing 3: Listing of Adhesion Score for Test Treatment (C) - M207 Arm 60 minutes43 
Summary Table 14.3.2: Descriptive Statistics by Treatment for Adhesion .............................. 44 
Summary Table 14.3.4: Descriptive Statistics by Treatment for ECG Parameters ................ 45 
Summary Table 14.3.4.1: Descriptive Statistics by Treatment for Vital Signs ........................ 46 
Summary Table 14.3.5: Descriptive Statistics by Treatment for Investigator Visual Skin 
Evaluation ................................................................................................................................ 47 
Summary Table 14.3.6: Frequency by Treatment for Investigator Visual Skin Evaluation .. 48 
Summary Table 14.3.7: Descriptive Statistics by Treatment for Adhesion .............................. 49 
Listing 14.2.1: Time (unit) and Plasma M207 Concentration (unit) Data of Test Treatment-
M207 Arm 30 minutes for Individual Subjects..................................................................... 50 


   
 
 
 
 
 
 
 
CP-2018-002 Version: Draft DD MMM YYYY              
  Confidential         
 
             Page 7 of 82                                                                   
Listing 14.2.2: Time (unit) and Plasma M207 Concentration (unit) Data of Test Treatment-
M207 Thigh 30 minutes for Individual Subjects .................................................................. 51 
Listing 14.2.3: Time (unit) and Plasma M207 Concentration (unit) Data of Test Treatment-
M207 Arm 60 minutes for Individual Subjects..................................................................... 52 
Listing 14.2.4: Time (unit) and Plasma M207 Concentration (unit) Data of Test Treatment-
INT Spray 2.5 mg for Individual Subjects ............................................................................ 53 
Listing 14.2.5: Pharmacokinetic Parameter and Ratio Values of zolmitriptan for Individual 
Subjects..................................................................................................................................... 54 
Listing 14.2.6: Pharmacokinetic Parameter Values of zolmitriptan for Individual Subjects . 55 
Listing 14.2.7: Pharmacokinetic Parameter Frel of zolmitriptan for Individual Subjects ..... 56 
Listing 14.2.8: Amount of Residual Drug on Used Test Treatment-A for Individual Subjects 
at 30 minutes (Upper Arm Application) ................................................................................ 57 
Listing 14.2.9: Amount of Residual Drug on Used Test Treatment-B for Individual Subjects 
at 30 minutes (Thigh Application) ......................................................................................... 58 
Listing 14.2.10: Amount of Residual Drug on Used Test Treatment-C for Individual 
Subjects at 60 minutes (Upper Arm Application) ................................................................ 59 
Listing 14.2.11: Amount of Residual Drug on Skin (3 Swabs) after removing Test 
Treatment-M207 Arm 30 minutes, Test Treatment-M207 Thigh 30 minutes and Test 
Treatment-M207 Arm 60 minutes for Individual Subjects ................................................. 60 
Listing 14.2.12: Listing of Adhesion Score for Test Treatment (A) - M207 Arm 30 minutes . 61 
Listing 14.2.13: Listing of Adhesion Score for Test Treatment (B) - M207 Thigh 30 minutes62 
Listing 14.2.14: Listing of Adhesion Score for Test Treatment (C) - M207 Arm 60 minutes . 63 
Listing 14.2.15: PK Blood Sampling Time Deviations ................................................................ 64 
Listing 16.1.6: Listing of Subjects Receiving Treatment ............................................................ 65 
Listing 16.2.1: Listing of Subject Disposition .............................................................................. 66 
Listing 16.2.2: Protocol Deviations ............................................................................................... 67 
Listing 16.2.2.1: Other Protocol Deviations ................................................................................. 68 
Listing 16.2.4: Demographic Data* .............................................................................................. 69 
Listing 16.2.7: Adverse Events Listings ....................................................................................... 70 
Listing 16.2.7.1: Listing of Prior and Concomitant Medication ................................................ 71 
Listing 16.2.8: Listing Drug Screen-Alcohol Breath Testing Results at Screening and at 
Admission/baseline .................................................................................................................. 72 
Listing 16.2.8.1: Listing Abnormal Clinically Significant Lab Results ..................................... 73 
Listing 16.2.8.2: Listing of Pregnancy Test Results Performed on Screening and 
Admission/baseline .................................................................................................................. 74 
Listing 16.2.8.3: Listing of Patch Retainment and Residual Drug Collection .......................... 75 
Listing 16.2.8.4: Listing of Vital Signs Assessments ................................................................... 76 
Listing 16.2.8.5: Listing of Medical History ................................................................................ 77 
Listing 16.2.8.6: Listing of Physical Examination at Screening and 12 hr ............................... 78 


   
 
 
 
 
 
 
 
CP-2018-002 Version: Draft DD MMM YYYY              
  Confidential         
 
             Page 8 of 82                                                                   
Listing 16.2.8.7: Listing of Adhesion Assessment at 30 Minute and 60 Minute ....................... 79 
Listing 16.2.8.8: Listing of  Investigator Visual Skin Evaluation at Pre-dose, 30 Minute, 60 
Minute, 12 hour, 24 hour and EOS/Early Term ................................................................... 80 
Listing 16.2.8.9: Listing of ECG performed on during Screening, Pre-dose, 15 minutes, 60 
minutes, 8 hour, 12 hour and End of Study .......................................................................... 81 
Figure 1: Linear Mean Plot of Zolmitriptan Treatments over Time ........................................ 82 
Figure 2: Mean Plot of Zolmitriptan Treatments over First 2 Hours ....................................... 82 
 


   
 
 
 
 
 
 
 
CP-2018-002 Version: Draft DD MMM YYYY              
  Confidential         
 
             Page 9 of 82                                                                   
1.0 
Introduction  
 
This statistical analysis plan (SAP) is intended to give a detailed description of the 
summaries and the analyses for the study. The analyses outlined in this document 
are designed in support of clinical protocol CP-2018-002.  
 
 
This Statistical Analysis Plan (SAP) should be finalized prior to database lock, 
final analysis of pharmacokinetics and before the treatment codes are applied to 
the analysis data.  
 
 
The Statistical analysis will be initiated after completion of impact assessment of 
protocol deviation. 
 
2.0 
Study Title 
 
A 
randomized 
open-label 
four-way 
crossover 
study 
to 
compare 
the 
pharmacokinetics, safety, and tolerability of M207 3.8 mg (administered as two 1.9 
mg patches) at two different application locations (upper arm and thigh) for 30 
minutes with intranasal zolmitriptan 2.5 mg and 1 hour wear time (upper arm) in 
healthy volunteers 
 
3.0 
Study Objectives 
 
1. To compare the pharmacokinetics, safety and tolerability of M207 3.8 mg 
administered to either the upper arm or thigh, particularly with respect to skin 
irritation (erythema, edema, bruising, bleeding) 
 
2. To compare the pharmacokinetics, safety and tolerability of M207 3.8 mg worn for 
either 30 minutes or 1 hour on the upper arm 
 
3. To compare the pharmacokinetics, safety and tolerability of M207 3.8 mg to 
intranasal zolmitriptan 2.5 mg 
 
4.0 
Study Description 
 
4.1 
Randomization and Blinding 
 
The 24 subjects are planned to receive each of the four treatments (A, B, C, D) 48 
hours apart. 
 
The order of receiving of the investigational products for each subject will be 
determined according to a randomization schedule which will be appropriate to the 
study design. Subjects will be randomized to one of the four sequences: either 
ABCD or BDAC or CADB or DCBA. Equal allocation of the sequence will be 
ensured.  
 
The randomization schedule will be generated using SAS® statistical software 
(Version: 9.4; SAS Institute Inc, USA), by a biostatistician of Cliantha Research 
Limited. The randomization schedule will be maintained under controlled access. 


   
 
 
 
 
 
 
 
CP-2018-002 Version: Draft DD MMM YYYY              
  Confidential         
 
             Page 10 of 82                                                                 
The personnel involved in the dispensing of investigational products will be 
accountable for ensuring compliance to randomization schedule.  
 
At the end of each dosing day, the safety data from the subjects will be evaluated. 
If tolerability is deemed to be acceptable by the Principal Investigator, a decision 
will be made to proceed to the next dosing day. 
 
4.2 
Pharmacokinetic Variables 
 
Serial blood sampling PK assessments will be performed at 0.00 (pre-dose), 2, 5, 
10, 15, 20, 30, 45, 60, 90 min, 2 hr, 4 hr, 8 hr, 12 hr and 24 hr post dose for each 
treatment period.  
 
Concentrations of zolmitriptan and it’s metabolite n-desmethyl zolmitriptan in 
plasma will be measured for the formulations using a validated assay. 
 
Based on the concentration data below pharmacokinetic parameters will be 
calculated using Phoenix® WinNonlin® professional software (Version 6.4 or 
higher).  
 
Pharmacokinetic Parameters: Cmax, Tmax, AUCt, AUCi, AUC(0-30mins), 
AUC(0-60mins), AUC(0-120mins), Kel, Tmax, tHalf and AUC_%Extrap_obs.  
 
4.3 
Safety Assessment 
 
The safety of zolmitriptan 2.5 mg and M207 3.8 mg patch will be assessed on the 
basis of:  
 
1) 
Vital signs monitoring  
2) 
Adverse Events (AEs) monitoring 
3) 
Clinical laboratory tests  
4) 
Physical examinations 
5) 
ECG 
6) 
Concomitant medications 
7) 
Investigator visual skin assessment 
 
4.4 
Sample Size  
 
No formal sample size calculation was performed. In previous studies of Zosano 
Pharma transdermal products in healthy volunteers, a sample size of 24 was 
sufficient to provide directional information on tolerability, as well as adequate 
information on pharmacokinetics, and comparative pharmacokinetics for various 
regimens. 
 


   
 
 
 
 
 
 
 
CP-2018-002 Version: Draft DD MMM YYYY              
  Confidential         
 
             Page 11 of 82                                                                 
4.5 
Study Design, Treatment and Plan 
 
This is a single-center, open-label, randomized, four-way crossover study. Each 
subject will receive each of the four study treatments once, followed by in-clinic 
monitoring and extensive blood sample collection for pharmacokinetic analysis. 
 
Dosing will occur approximately 48 hours apart, until completion of dosing in 
randomized order per the treatment sequence tables. Plasma samples from the 
dosing days will be sent to the analytical laboratory for analysis and tolerability for 
each of the dose levels will be summarized. 
 
After completion of the four dosing days, subjects will be assessed one final time 
and dismissed from the study. 
 
Investigational Products: 
 
M207 Intracutaneous Microneedle System 
 
The Zosano M207 Intracutaneous Microneedle System is a novel drug delivery 
technology which consists of a disposable titanium patch centered on an adhesive 
backing with microneedles that are dry-coated with the drug product formulation, 
and a reusable handheld applicator that ensures that the patch is applied with a 
defined application speed and energy to the site of administration. 
 
M207 systems consist of zolmitriptan coated titanium array with an adhesive 
backing that is applied using proprietary patch applicators. Descriptions of the 1.9 
mg patches used in the study are described below. 
 
Zolmitriptan Nasal Spray 
 
Zolmitriptan nasal spray is a commercially available product (Zomig® Nasal 
Spray) and will be purchased for use in this study. The dose used in this study will 
be 2.5 mg/0.1 ml. This dose should be administered to either the right or left nostril 
with the subject’s head tilted slightly backward. 
 
M207 1.9 mg  
 
The M207 1.9 mg consists of a 3 cm2 titanium array of microprojections that are 
nominally 340 μm in length coated with 1.9 mg of zolmitripan. The array is 
applied to the center of a 5 cm2 tan adhesive patch. The patch is attached to the 
interior of a white to off-white polycarbonate ring co-molded with a desiccant, 
packaged in a cup. 
 
Study treatments are:  
Treatment A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear 
time (upper arm application) 
 
Treatment B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear 
time (thigh application) 


   
 
 
 
 
 
 
 
CP-2018-002 Version: Draft DD MMM YYYY              
  Confidential         
 
             Page 12 of 82                                                                 
 
Treatment C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time 
(upper arm application) 
 
Treatment D: Intranasal zolmitriptan 2.5mg 
 
4.6 
Subject Population  
 
The study population will consist of 24 healthy volunteers (12 women and 12 men) 
18 to 50 years of age in general good health. 
 
4.7 
Number of Subjects 
A sufficient number of subjects will be enrolled to ensure application of 24 healthy 
subjects. 
4.8 
Study Duration 
 
Screening is 1 day (up to 30 days prior to dosing); in-clinic duration of study 
participation for each subject is approximately 2 weeks total (includes 4 treatment 
periods), and the final end of study visit occurs on one day. 
 
4.9 
Withdrawal/Discontinuation Criteria 
 
The Participation in the study is completely voluntary and a subject can choose to 
withdraw from the study at any time. In addition, a subject can be withdrawn for 
any of the following reasons: the Principal Investigator decides that continuing the 
drug may be harmful, a subject is non-compliant with the protocol, a subject has a 
serious reaction to the treatment, or the study is stopped by the Independent Ethics 
Committee, US Food and Drug Administration (FDA), or Zosano Pharma. 
 
In order to complete all treatments for each dose, additional subjects may be 
enrolled to account for subjects who withdraw or are discontinued from the study. 
If a subject does not complete all planned treatments, the reason and date of 
withdrawal from the study must be recorded in the CRF. Zosano Pharma should be 
notified immediately if a subject withdraws prematurely from the study. 


   
 
 
 
 
 
 
 
CP-2018-002 Version: Draft DD MMM YYYY              
  Confidential         
 
             Page 13 of 82                                                                 
5.0 
Endpoints 
5.1 
Safety and Tolerability 
 
 Incidence of adverse events 
 
 Change in physical examination findings from pre-dose to 12 hours post-
dose 
 
 Changes in vital signs from pre-dose to 10 min, 60 min, 2 hour, 4 hour, and 
12 hour post-dose 
 
 Changes in ECG parameters from pre-dose to 15 min, 60 min, 8 hour, and 
12 hour post-dose 
 
 Scores from an investigator visual skin assessment for erythema, edema, 
bruising and bleeding at the patch application sites from pre-dose to 30 min 
(for 30 min wear time treatment assignments only), 60 min (for 60 min 
wear time treatment assignment only), 12 hour and 24 hour post-dose 
 
 Changes in clinical labs from screening to end of study 
 
 Patch adhesion score at time of application at 30 min and 60 min post-dose 
(for 60 min wear time treatment assignment only) 
5.2 
Safety Overview 
 
M207 consisting of two patches of 1.9 mg (3.8 mg), 30 minute upper arm 
application, has been studied in healthy volunteers (in clinic) and subjects with 
migraine (outpatient). This regimen has been generally well-tolerated, with adverse 
events observed (dizziness and chest tightness) of those typically reported for 
triptans. Adverse events reported were almost always within the first few minutes 
after patch application. It is anticipated that systemic exposure with forearm 
application will be not significantly different than that seen with upper arm 
application, based on our experience with glucagon. Also, since Cmax was 
generally observed, on average, at around 15 minutes, wearing the patches for 1 
hours will probably not be associated with higher Cmax levels than 30 minutes and 
should not result in different tolerability issues. 
 
6.0 
Study Populations (Definition of Populations for Analysis)  
 
6.1 
Pharmacokinetic Population 
PK population is defined as below:  
 
 Concentration data of subjects, who complete at least two periods of the study, 
will be included in the pharmacokinetic and statistical analysis. Concentration 


   
 
 
 
 
 
 
 
CP-2018-002 Version: Draft DD MMM YYYY              
  Confidential         
 
             Page 14 of 82                                                                 
and pharmacokinetic data of other subjects will be presented in the report if 
available, but will not be included in the statistical analysis. 
 Data from any subject with missing concentration values in any period (like 
missed blood samples, lost samples, samples unable to be quantitated) may be 
used for bioavailability evaluation if pharmacokinetic parameters can be reliably 
estimated using the remaining data points otherwise that specific pharmacokinetic 
parameter data will be excluded from the bioavailability evaluation.  
 If any subject has all BLQ/zero values in any period, then the subject will be 
excluded from the bioavailability evaluation analysis from that particular period. 
 If the pre-dose concentration appears to be >5% of the Cmax in any subject in 
any period, then the subject will be excluded from the statistical analysis in that 
period. 
 Kel and related elimination phase parameters will not be estimated for cases that 
do not exhibit a terminal log-linear phase in the concentration versus time profile. 
6.2 
Safety Population 
 
Safety analysis will be performed on all randomized subjects receiving at least one 
dose of investigational product. Subjects’ safety data will be presented according 
to the treatment they actually received. 
 
Drop-outs within a 24-hour period are not anticipated; however should they occur 
prior to 2 hours after patch application then additional eligible subjects may be 
enrolled. 
 
7.0 
Incomplete and Missing Data 
 
No adjustment or imputation will be utilized for missing values or for subjects who 
withdraw prior to completing the study. In case of missing data for skin 
assessment, LOCF (last observation carried forward) method will be used. 
 
8.0 
Study Subjects and Conduct 
 
Subject accountability will be tabulated for each study treatment and for all 
subjects combined by summarizing the number of subjects who are randomly 
assigned to treatment, complete the study, prematurely discontinue, and the reason 
for discontinuation. A listing will be presented to describe dates of withdrawal and 
the reason for discontinuation for each discontinued subject. A listing of study 
treatment administration will be provided. 
 
9.0 
Demographic Characteristics 
 
Individual subject demographics will be presented in listings. Demographic 
characteristics such as age, gender, race, ethnicity, height, weight and body mass 
index (BMI) will be summarized and tabulated for all randomized subjects. 
Descriptive statistics will be presented for age, height, weight and BMI. Frequency 
counts and percentage will be presented for gender, race and ethnicity. 


   
 
 
 
 
 
 
 
CP-2018-002 Version: Draft DD MMM YYYY              
  Confidential         
 
             Page 15 of 82                                                                 
 
10.0 Prior and Concomitant Medications 
 
Subjects will be asked to refrain from taking either prescription or OTC 
medications from the time of Screening until the completion of the study, except 
for those discussed in this section. All concomitant medications taken during the 
study will be recorded on the concomitant medications case report form (CRF) 
with indication for use, totally daily dosage, and dates of drug administration. 
 
Subjects must discontinue use of herbal or over-the-counter medications (with the 
exception of all medications listed below) for 48 hours prior to treatment days and 
throughout the study. 
 
If the medication end date is known and medication end date is prior to the first 
dose of study treatment it will be classified under prior medication. If the end date 
of the medication is unknown, it will be considered as concomitant medication. A 
subject listing of all prior and concomitant medications and related information 
(e.g.: dose, unit, frequency etc.) will be presented. 
 
11.0 Pharmacokinetic Analysis 
 
Pk analysis will be performed on the pharmacokinetic population (see section 6.1). 
 
All Below Limit of Quantitation (BLQ) concentration values will be set to zero 
before pharmacokinetic analysis, except in the case where there is a measurable 
value immediately preceding the BLQ value and a measurable value immediately 
after the BLQ value.  In these instances, the BLQ value will be set to missing. 
 
The actual time of blood collection for all samples collected will be used in the 
calculation of pharmacokinetic parameters. 
 
Pharmacokinetic parameters: The following pharmacokinetic parameters will be 
determined from the time and concentration data using a non-compartmental 
analysis of WinNonlin® professional software (Phoenix® version 6.4 or higher; 
Pharsight Corporation, USA). 
 
Cmax: Maximum measured plasma concentration over the time span specified. 
 
Tmax:  Time of the maximum measured plasma concentration. If the maximum 
plasma concentration occurs at more than one time point, the first is chosen as 
Tmax. 
 
AUCt: The area under the plasma concentration versus time curve will be 
calculated using the linear trapezoidal rule from the zero time point to the last 
quantifiable concentration. 
 


   
 
 
 
 
 
 
 
CP-2018-002 Version: Draft DD MMM YYYY              
  Confidential         
 
             Page 16 of 82                                                                 
AUCi: The area under the plasma concentration versus time curve from zero to 
infinity will be calculated by adding Ct/Kel to AUCt, where Ct is the last 
quantifiable concentration and Kel is the elimination rate constant. 
 
AUC(0-30mins): The area under the plasma concentration versus time curve will 
be calculated using the linear trapezoidal rule from the time zero to 30 minutes. 
 
AUC(0-60mins): The area under the plasma concentration versus time curve will 
be calculated using the linear trapezoidal rule from the time zero to 60 minutes. 
 
AUC(0-120mins): The area under the plasma concentration versus time curve will 
be calculated using the linear trapezoidal rule from the time zero to 120 minutes. 
 
Kel: The terminal elimination rate constant will be obtained from the slope of the 
line, fitted by linear least squares regression, through the terminal points of the log 
(base e) of the concentration versus time plot for these points. 
 
tHalf: The half-life will be calculated by the equation tHalf = 0.693/ Kel 
 
AUC_%Extrap_obs:  The residual area in percentage will be determined by the 
formula, [(AUCi - AUCt)/ AUCi] x 100 
 
Frel – Relative  Bioavailability.  
 
Bioavailability relative to other treatment sites of application and wear times will 
be calculated using the below mentioned formula; 
 
Formula for calculation of Frel; 
Frel = 100*(AUCX*DY) / (AUCY*DX); where relative bioavailability measures the 
bioavailability (estimated as the AUC) of a treatment-X when compared with 
treatment-Y of the same drug. D is the dose administered. 
 
Frel will be calculated for AUCt. 
 
Ratios will be reported for AUC(0-30mins), AUC(0-60mins), AUC(0-120mins), 
AUCt, AUCi and Cmax. 
 
No value of Kel, AUCi or tHalf will be reported for cases that do not exhibit a 
terminal log-linear phase in the concentration versus time profile. 
 
 Descriptive statistics: Mean, standard deviation, coefficient of variance, 
Median, Maximum and Minimum for applicable pharmacokinetic parameters 
will be calculated. 


   
 
 
 
 
 
 
 
CP-2018-002 Version: Draft DD MMM YYYY              
  Confidential         
 
             Page 17 of 82                                                                 
 Statistical 
analysis: 
Statistical 
analysis 
will 
be 
performed 
on 
pharmacokinetic data of subjects using SAS® statistical software (Version: 9.4 
or higher; SAS Institute Inc, USA).  
 Analysis of Variance:  Ln-transformed data of Cmax, AUC(0-30mins), 
AUC(0-60mins), AUC(0-120mins), AUCt and AUCi will be evaluated 
statistically using the PROC MIXED procedure from SAS® for difference due 
to treatment, with period and sequence as a fixed effects and subject within 
sequence as a random effect.   
All main effects will be tested at 5% level of significance using the Mean 
Square Error as the error term. 
 Two one-sided 90% confidence intervals for the ratio of means between drug 
formulations will be calculated for Ln-transformed data of Cmax, AUC(0-
30mins), AUC(0-60mins), AUC(0-120mins), AUCt and AUCi.  
The data of metabolite n-desmethyl zolmitriptan will be provided as supportive 
information. 
 
The comparisons of interest will be treatment A vs. B, A vs. C, A vs. D,  
B vs. C, B vs. D and C vs. D. 
 
12.0 Assessment Details 
 
Clinical Laboratory Tests 
 
Standard clinical laboratory tests (serum pregnancy for all women, CBC, 
hematology, and urinalysis) will be performed at Screening and End of Study (or 
early termination) and urine pregnancy testing for all women at each 
Admission/baseline visit. 
 
A blood sample at screening will be taken to perform serological tests for HIV, 
Hepatitis B and Hepatitis C. 
 
Urine drug screen and alcohol (breath) testing will be performed at screening and 
each Admission/baseline visit. Urine drug screen will test for amphetamine, 
barbituates, 
cocaine, 
cannabinoids, 
phencyclidine 
(PCP), 
opioids, 
and 
methamphetamines. 
 
Samples will be analyzed by a local laboratory.  
 
Vital Signs 
 
Vital signs include heart rate, pulse, respiratory rate, as well as systolic and 
diastolic arterial pressure. Vital signs will be recorded after subjects have been in 
the seated resting position for 2 minutes. Temperature will be taken at Screening, 
admission/baseline, and at end of study visit/or early termination only. 
 
Electrocardiograms 
 


   
 
 
 
 
 
 
 
CP-2018-002 Version: Draft DD MMM YYYY              
  Confidential         
 
             Page 18 of 82                                                                 
A standard 12-lead ECG will be performed by a qualified individual at the site. 
General morphology and intervals [Heart rate, QRS, PR interval, QRS, QTn, 
QTcf], of interest will be assessed with each tracing. The principal or sub-
investigator must review the tracing and assess it for any clinically significant 
abnormality.  
 
Investigator Visual Skin Assessments of the Application Sites 
 
Each M207 patch site (where a patch has been removed) will be observed for the 
following skin assessments pre-dose and immediately after removal of the patches 
from the subject’s skin (and before swabbing) at 30 min (for 30 min wear time 
treatment groups only), 60 min, 12 hr, 24 hr and at the End of Study/or Early 
Termination visit. 
 
Erythema 
 
The erythema evaluations will be performed using the following scale: 
 
 0 = None 
 1 = Mild redness 
 2 = Moderate colored redness 
 3 = Beet colored redness 
 
Edema 
 
The edema evaluations will be performed using the following scale: 
 
 0 = None 
 1 = Slight edema 
 2 = Moderate edema 
 3 = Severe edema 
 
Bruising 
 
Bruising assessments (visual rating) will be performed using the following scale: 
 
 0 = None 
 1 = ≤ 25% application site has bruising spots 
 2 = ≥ 26 to ≤ 50% application site has bruising spots 
 3 = > 50% application site has bruising spots 
 
Bleeding 
 
Bleeding will be assessed using the following scale: 
 
 0 = None 
 1 = Pink color on skin 
 2 = Visible blood drop 
 3 = Active bleeding 


   
 
 
 
 
 
 
 
CP-2018-002 Version: Draft DD MMM YYYY              
  Confidential         
 
             Page 19 of 82                                                                 
 
For example; 
 
Skin assessment score presented in Table-A will be modified as presented in 
Table-B for statistical analysis using LOCF method. 
 
Table-A  
Subject 
Skin assessment scoring_Time Points(Hrs) 
0.0 
30 minutes 
60 minutes 
12 hour 
24 hour 
1 
0 
0 
0 
2 
2 
2 
0 
2 
2 
3 
Missing 
3 
0 
1 
2 
2 
Missing 
 
 
Table-B 
Subject 
Skin assessment scoring_Time Points(Hrs) 
0.0 
30 minutes 
60 minutes 
12 hour 
24 hour 
1 
0 
0 
0 
2 
2 
2 
0 
2 
2 
3 
3 
3 
0 
1 
2 
2 
2 
 
Patch Adhesion Assessment 
 
Patch adhesion assessment at the time of application and at 30 min and 60 min 
post-dose (for 60 min wear time treatment group only) will be checked for the 
degree of adhesion by investigators should use a 5-point numerical scale in which 
each score corresponds to a specified range of adhered surface area of each patch, 
as follows: 
 
0 = ≥ 90% adhered (essentially no lift off the skin) 
 
1 = ≥ 75% to < 90% adhered (some edges only lifting off the skin) 
 
2 = ≥ 50% to < 75% adhered (less than half of the patch lifting off the skin) 
 
3 = > 0% to < 50% adhered (not detached, but more than half of the patch lifting 
off the skin without falling off) 
 
4 = 0% adhered (patch detached; completely off the skin). 
 
For example; 


   
 
 
 
 
 
 
 
CP-2018-002 Version: Draft DD MMM YYYY              
  Confidential         
 
             Page 20 of 82                                                                 
 
Adhesion Data: 
 
Actual Adhesion score presented in below Table; 
 
Subject 
Adhesion  scoring_Time Points(Hrs) 
0.0 
30 minutes 
60 minutes 
1 
0 
0 
0 
2 
0 
2 
2 
3 
0 
1 
1 
 
13.0 Subject Disposition 
An overall summary of subject’s disposition will be presented using a clear 
accounting of all subjects who entered the study, subjects who completed the study 
and subjects who do not complete the study, along with the reason of not 
completing the study. Randomized subjects who do not complete the study due to 
any reason will be considered as withdrawal. 
Subject wise data listings will be sorted by subject number; listing will include 
subject number, treatment, reason for discontinuation, discontinuation period, date 
& time. 
14.0 Protocol Deviations/Violation 
Protocol Deviation is defined as less serious non-compliance which needs 
adequate documentation and Protocol Violation is defined as serious non-
compliance with the protocol resulting in the exclusion of a randomized subject 
from the study. Listing will be provided for subjects with protocol 
deviation/violation in the study. 
15.0 Handling of data from visit 
Tabulation of descriptive statistics will be performed primarily using SAS® 
(release 9.4 or higher).  
16.0 Safety Analyses 
Safety analyses will be performed on safety population set (refer section 6.2).  All 
safety data will be listed by subject, treatment group and parameter, separate 
listings of all abnormal laboratory findings will be provided, and clinically 
significant abnormalities will be recorded as AEs. 
 
16.1 Adverse Events 
 
Adverse events (AEs) will be mapped to preferred term and body-organ system 
using MedDRA™. The number and percentage of subjects reporting AEs will be 


   
 
 
 
 
 
 
 
CP-2018-002 Version: Draft DD MMM YYYY              
  Confidential         
 
             Page 21 of 82                                                                 
summarized by AE preferred term and AE body-organ system. Adverse events will 
be summarized by severity and relationship to study drug also. 
 
In particular, AE summary tables will be presented for the following: 
 
AE overview 
 
AE incidence 
 
AEs by severity 
 
AEs leading to study drug discontinuation  
 
AEs by relationship 
 
Each participant will be counted only once within each summation level (SOC; 
preferred term). If a participant experiences more than one AE within each 
summation level only, the AE with the strongest relationship or the maximum 
severity, as appropriate, will be included in the summaries of relationship and 
severity. 
 
Adverse events will be attributed to the most recent dose taken, i.e., AEs occurring 
post-dose but prior to the next dose, will be attributed to the most recent dose by 
using the date and time the AE occurred.  Adverse events occurring after the first 
dose of study drug are considered treatment emergent.  
 
16.1.1 Missing and Partial AE Onset Date/Time 
 
In the event that only a partial end date (month/year) is available, and month/year 
occurs before that of the first study drug administration date, the adverse event will 
be considered as non-treatment emergent. However, if the onset date is a partial 
date (month/year) and month/year occurs on or after that of study drug 
administration date, the following cases will be considered: 
 
 If month/year of the onset date is greater than the month/year of study drug 
administration date, the adverse event will be considered treatment-
emergent. 
 
 If month/year of the onset date is equal to the month/year of study drug 
administration date, and the end date is present, the end date will be used to 
determine if the adverse event is treatment emergent. If the end date is on 
or after study drug administration date, the adverse event will be 
considered treatment-emergent; otherwise, if the adverse event stopped 
before study drug administration date, then it will not be treatment-
emergent;  
 
 If month/year of the onset date is equal to the month/year of study drug 
administration date, and the end date is a partial date, the adverse event will 
be considered treatment emergent. 
 
 If adverse event onset date is known and time is missing then the time will 
be considered as post dose. 
 


   
 
 
 
 
 
 
 
CP-2018-002 Version: Draft DD MMM YYYY              
  Confidential         
 
             Page 22 of 82                                                                 
16.2 Vital Signs 
 
Descriptive summaries of actual values and changes from pre-dose to 10 min, 60 
min (1 hr), 120 min, 240 min (4 hr), and 720 minutes (12 hr) post-dose will be 
calculated for heart rate, systolic blood pressure, and diastolic blood pressure and 
presented by treatment group.  
 
16.3 ECG 
 
Descriptive summaries of actual values and changes from pre-dose by treatment 
group will also be provided for the quantitative ECG parameters of rhythm, heart 
rate, PR interval, QRS interval, QT, QTcF, (Fridericia’s) corrections for heart rate.  
 
16.4 Investigator Skin Assessments 
 
Scores of the investigator skin assessments of the application sites at 30 min (30 
min wear time assignment only), 60 min (1 hr), 12 hours and 24 hours post-dose 
will be summarized by treatment group using frequency tables. 
 
16.5 Clinical Laboratory Evaluations 
 
Clinical laboratory values will be displayed in data listings, including a listing of 
all abnormal results.  Clinically significant values will be flagged. 
 
16.6 Physical examination 
 
Results of physical examinations conducted throughout the study will be presented 
in data listings, including abnormalities.  
17.0 Medical history 
Medical history data will be presented in listings.  
18.0 Patch Adhesion  
 
Adhesion scores will be summarized by time point and treatment group using 
frequency tables. Mean adhesion scored by time point and treatment group will 
also be provided. The means of the per treatment group mean adhesion score for 
the different test products will be compared. 
 
19.0 Residual Drug Analyses 
 
Analyses will be performed to quantify the amount of drug remaining on the M207 
patch system and the amount of drug recovered from the skin of the subject 
following removal of each of the patches. A description of the disposition of the 
remaining drug will be presented. The results from analysis of residual 
zolmitriptan on the skin and the residual zolmitriptan on the used patches will 
provide a basis for the calculation of the total amount of drug delivered from each 
treatment. 
 


   
 
 
 
 
 
 
 
CP-2018-002 Version: Draft DD MMM YYYY              
  Confidential         
 
             Page 23 of 82                                                                 
20.0 Extent of Exposure 
 
Extent of exposure summarizes the actual number of treatments received by all 
dosed subjects, the amount of drug dosed and the total cumulative dose received 
by each subject over the course of the study.  


                                                                                                                                                    
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  Confidential         
 
            Page 24 of 82                                                
 
Mock Tables 
 
For all the summary and analysis tables, reference of listing and generation date & 
time of table will be provided, and for the listing generation date & time of listing 
will be provided. All summary and analysis tables will be provided in CSR based 
on the ICH E3 guideline. Given mock tables can be added or modified based on 
study requirement. 
  


   
 
 
 
 
 
 
 
CP-2018-002 Version: Draft DD MMM YYYY              
  Confidential         
 
             Page 25 of 82                                                                 
Summary Table 12.1: Extent of Exposure for all Dosed Subjects 
 
 
Subject 
Treatment Received 
Total Number 
of Doses Taken 
Treatment 
Dose 
Total 
Exposure 
Subjects Who Completed the Study 
XX, XX 
ABCD 
X 
XX mg 
XX mg 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subjects Who Discontinued Prematurely 
 
XXXX 
ABCD 
X 
XX mg 
XX mg 
Treatment A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper 
arm application) 
Treatment B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh 
application) 
Treatment C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper 
arm application) 
Treatment D: Intranasal zolmitriptan 2.5mg 
 
 


                                                                                                                                                    
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  
 
 
 Confidential         
 
            
 
 
 Page 26 of 82                                                        
 
Summary Table 14.1.1: Summary of Subject Disposition 
 
 
Sequence 
Total 
 
ABCD
BDAC 
CADB 
DCBA 
Subjects Randomized 
XX 
XX 
XX 
XX 
XX 
Subjects Treated (Safety Population) 
XX 
XX 
XX 
XX 
XX 
Subjects Completed 
XX (%) XX (%) XX (%) 
XX (%) 
XX (%) 
Subjects Discontinued 
XX (%) XX (%) XX (%) 
XX (%) 
XX (%) 
      Adverse Event 
XX (%) XX (%) XX (%) 
XX (%) 
XX (%) 
      Non Compliance 
XX (%) XX (%) XX (%) 
XX (%) 
XX (%) 
      Physician Decision 
XX (%) XX (%) XX (%) 
XX (%) 
XX (%) 
    Withdrawal by Subject 
XX (%) XX (%) XX (%) 
XX (%) 
XX (%) 
     Study Termination 
XX (%) XX (%) XX (%) 
XX (%) 
XX (%) 
      Other 
 
 
 
 
 
Treatment A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application) 
Treatment B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application) 
Treatment C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application) 
Treatment D: Intranasal zolmitriptan 2.5mg 
 
Note: Percentages are calculated using the number of subjects treated as the denominator. 
Note: Subject 104 was randomized to sequence CADB but was given sequence ABCD. 
Note: Subject XXX dropped out after Period Y due to personal reasons. 
 


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  
 
 
 Confidential         
 
            
 
 
 Page 27 of 82                                                                          
                                                                                                                                                                                                                                                                                                           
Summary Table 14.1.2.1: Summary of Demographics 
 
 
Dosed 
Completed 
Subjects 
N 
XX 
XX 
 
Gender, n (%) 
Male 
XX (XX.XX%) 
XX (XX.XX%) 
 
Female 
XX (XX.XX%) 
XX (XX.XX%) 
 
Ethnicity, n (%) 
Not Hispanic or Latino 
XX (XX.XX%) 
XX (XX.XX%) 
 
Hispanic or Latino 
XX (XX.XX%) 
XX (XX.XX%) 
 
Race, n (%) 
Asian 
XX (XX.XX%) 
XX (XX.XX%) 
 
White 
XX (XX.XX%) 
XX (XX.XX%) 
 
Black or African American 
XX (XX.XX%) 
XX (XX.XX%) 
 
Native Hawaiian or Other Pacific Islander 
XX (XX.XX%) 
XX (XX.XX%) 
 
American Indian or Alaska Native 
XX (XX.XX%) 
XX (XX.XX%) 
 
Other 
XX (XX.XX%) 
XX (XX.XX%) 
 
Multiple 
XX (XX.XX%) 
XX (XX.XX%) 
 
Age (Years) 
Mean (±SD) 
XX (±X) 
XX (±X) 
 
Median 
XX 
XX 


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  
 
 
 Confidential         
 
            
 
 
 Page 28 of 82                                                                          
                                                                                                                                                                                                                                                                                                           
 
Dosed 
Completed 
 
Min 
XX 
XX 
 
Max 
XX 
XX 
 
BMI (kg/m2) 
Mean (±SD) 
XX.X (±X.X) 
XX.X (±X.X) 
 
Median 
XX.X 
XX.X 
 
Min 
XX.X 
XX.X 
 
Max 
XX.X 
XX.X 
 
Height (cm) 
Mean (±SD) 
XX.X (±X.X) 
XX.X (±X.X) 
 
Median 
XX.X 
XX.X 
 
Min 
XX.X 
XX.X 
 
Max 
XX.X 
XX.X 
 
Weight (kg) 
Mean (±SD) 
XX.X (±X.X) 
XX.X (±X.X) 
 
Median 
XX.X 
XX.X 
 
Min 
XX.X 
XX.X 
 
Max 
XX.X 
XX.X 
 
Note: - BMI: Body Mass Index, N = Number of subjects in each group, n=number of subjects in each category. 


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  
 
 
 Confidential         
 
            
 
 
 Page 29 of 82                                                                          
                                                                                                                                                                                                                                                                                                           
Summary Table 14.1.2.2. Summary of Mean Demographic Data (± SD) 
 
 
All Subjects Dosed 
(N = XX) 
Subjects Completed 
(N = XX) 
Subjects Included in PK Analysis 
(N = XX) 
All 
(N = XX) 
Males 
(N = XX) 
Females 
(N = XX) 
All 
(N = XX) 
Males 
(N = XX) 
Females 
(N = XX) 
All 
(N = XX) 
Males 
(N = XX) 
Females 
(N = XX) 
Age (years) 
XX.X (±XX.XX) 
XX.X (±XX.XX) 
XX.X (±XX.XX) 
Weight (kg) 
XX.X (±XX.XX) 
XX.X (±XX.XX) 
XX.X (±XX.XX) 
Height (cm) 
XX.X (±XX.XX) 
XX.X (±XX.XX) 
XX.X (±XX.XX) 
BMI (kg/m2) 
XX.X (±XX.XX) 
XX.X (±XX.XX) 
XX.X (±XX.XX) 


                                                                                                                                                    
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  
 
 
 Confidential         
 
            
 
 
 Page 30 of 82                                                                          
 
 
Summary Table 14.2.1.1: Descriptive Statistics of Zolmitriptan Pharmacokinetic Parameters  
 
Variable / Parameters 
Cmax (Unit) 
AUCt (Unit) 
Treatment 
(A) - M207 
Arm 30 
minutes 
Treatment 
(B) - M207 
Thigh 30 
minutes 
Treatment 
(C) - M207 
Arm 60 
minutes 
Treatment 
(D) - INT 
Spray 2.5 
Treatment 
(A) - 
M207 
Arm 30 
minutes 
Treatment 
(B) - M207 
Thigh 30 
minutes 
Treatment 
(C) - 
M207 
Arm 60 
minutes 
Treatment 
(D) - INT 
Spray 2.5 
N 
Mean 
Std Dev 
Minimum 
Median 
Maximum 
Coeff of Variation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable / Parameters 
Tmax (Unit) 
Kel (Unit) 
Treatment 
(A) - M207 
Arm 30 
minutes 
Treatment 
(B) - M207 
Thigh 30 
minutes 
Treatment 
(C) - M207 
Arm 60 
minutes 
Treatment 
(D) - INT 
Spray 2.5 
Treatment 
(A) - 
M207 
Arm 30 
minutes 
Treatment 
(B) - M207 
Thigh 30 
minutes 
Treatment 
(C) - 
M207 
Arm 60 
minutes 
Treatment 
(D) - INT 
Spray 2.5 
N 
Mean 
Std Dev 
Minimum 
Median 
Maximum 
Coeff of Variation 
 
 
 
 
 
 
 
 
 
 
 
 
 


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  
 
 
 Confidential         
 
            
 
 
 Page 31 of 82                                                                          
                                                                                                                                                                                                                                                                                                           
 
Variable / Parameters 
AUC0-0.5 (Unit) 
AUC0-1 (Unit) 
Treatment 
(A) - M207 
Arm 30 
minutes 
Treatment 
(B) - M207 
Thigh 30 
minutes 
Treatment 
(C) - M207 
Arm 60 
minutes 
Treatment 
(D) - INT 
Spray 2.5 
Treatment 
(A) - 
M207 
Arm 30 
minutes 
Treatment 
(B) - M207 
Thigh 30 
minutes 
Treatment 
(C) - 
M207 
Arm 60 
minutes 
Treatment 
(D) - INT 
Spray 2.5 
N 
Mean 
Std Dev 
Minimum 
Median 
Maximum 
Coeff of Variation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable / Parameters 
AUC0-2 (Unit) 
AUCi (Unit) 
Treatment 
(A) - M207 
Arm 30 
minutes 
Treatment 
(B) - M207 
Thigh 30 
minutes 
Treatment 
(C) - M207 
Arm 60 
minutes 
Treatment 
(D) - INT 
Spray 2.5 
Treatment 
(A) - 
M207 
Arm 30 
minutes 
Treatment 
(B) - M207 
Thigh 30 
minutes 
Treatment 
(C) - 
M207 
Arm 60 
minutes 
Treatment 
(D) - INT 
Spray 2.5 
N 
Mean 
Std Dev 
Minimum 
Median 
Maximum 
Coeff of Variation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  
 
 
 Confidential         
 
            
 
 
 Page 32 of 82                                                                          
                                                                                                                                                                                                                                                                                                           
 
Variable / Parameters 
tHalf (Unit) 
AUC_Extp_obs (Unit) 
Treatment 
(A) - M207 
Arm 30 
minutes 
Treatment 
(B) - M207 
Thigh 30 
minutes 
Treatment 
(C) - M207 
Arm 60 
minutes 
Treatment 
(D) - INT 
Spray 2.5 
Treatment 
(A) - 
M207 
Arm 30 
minutes 
Treatment 
(B) - M207 
Thigh 30 
minutes 
Treatment 
(C) - 
M207 
Arm 60 
minutes 
Treatment 
(D) - INT 
Spray 2.5 
N 
Mean 
Std Dev 
Minimum 
Median 
Maximum 
Coeff of Variation 
 
 
 
 
 
 
 
 
 
 
 
 
 


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  
 
 
 Confidential         
 
            
 
 
 Page 33 of 82                                                                          
                                                                                                                                                                                                                                                                                                           
Summary Table 14.2.1.2: Descriptive statistics of Zolmitriptan concentration (unit) data  
 
Treatment (A) - 
M207 Arm 30 
minutes 
Variable 
Time (hrs) 
 0.000 
0.033 
 0.083 
0.167 
0.250 
0.333 
0.500 
0.750 
1.000 
1.500 
2.000 
4.000 
8.000 
12.000 
24.000 
N 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Mean 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Std Dev 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Minimum 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Median 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Maximum 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Coeff of Variation 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Treatment (B) - 
M207 Thigh 30 
minutes 
N 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Mean 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Std Dev 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Minimum 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Median 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Maximum 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Coeff of Variation 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  
 
 
 Confidential         
 
            
 
 
 Page 34 of 82                                                                          
                                                                                                                                                                                                                                                                                                           
 
Treatment (C) - 
M207 Arm 60 
minutes 
Variable 
Time (hrs) 
 0.000 
0.033 
 0.083 
0.167 
0.250 
0.333 
0.500 
0.750 
1.000 
1.500 
2.000 
4.000 
8.000 
12.000 
24.000 
N 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Mean 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Std Dev 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Minimum 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Median 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Maximum 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Coeff of Variation 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Treatment (D) - 
INT Spray 2.5 
N 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Mean 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Std Dev 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Minimum 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Median 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Maximum 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Coeff of Variation 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
Note: All the above provided concentration descriptive will also be provided for metabolite n-desmethyl zolmitriptan as a supportive 
information. 


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  
 
 
 Confidential         
 
            
 
 
 Page 35 of 82                                                                          
                                                                                                                                                                                                                                                                                                           
Summary Table 14.2.2.1: Summary of Statistical Analysis for M207 patches compared to Intranasal zolmitriptan 
 
PARAMETER 
INT Spray 2.5 
(D) LEAST 
SQUARE MEANS 
Ln DATA 
M207 Arm 30 (A) 
LEAST SQUARE 
MEANS Ln 
DATA 
M207 Arm 60 
(C) LEAST 
SQUARE 
MEANS Ln 
DATA 
M207 Thigh 30 
(B) LEAST 
SQUARE 
MEANS Ln 
DATA 
INT Spray 2.5 
(D)GEOMET
RIC MEANS 
M207 Arm 
30 
(A)GEOM
ETRIC 
MEANS 
M207 
Thigh 30 
(B)GEOME
TRIC 
MEANS 
M207 Arm 
60 (C) 
GEOMET
RIC 
MEANS 
Cmax 
 
 
 
 
 
 
 
 
AUCt 
 
 
 
 
 
 
 
 
AUC(0-0.5hr) 
 
 
 
 
 
 
 
 
AUC(0-1hr) 
 
 
 
 
 
 
 
 
AUC(0-2hr) 
 
 
 
 
 
 
 
 
AUCi 
 
 
 
 
 
 
 
 
 
PARAMETER 
INTRA-
SUBJECT CV 
(%) 
(M207 Arm 30 
(A)/ INT Spray 
2.5 (D))RATIO 
(M207 Thigh 30 
(B)/ INT Spray 
2.5 (D))RATIO 
(M207 Arm 60 
(C)/ INT Spray 
2.5 (D))RATIO 
(M207 Arm 30 
(A)/ M207 Thigh 
30 (B))RATIO 
(M207 Arm 30 
(A)/ M207 
Arm 60 
(C))RATIO 
(M207 Thigh 30 
(B)/ M207 Arm 
60 (C))RATIO 
Cmax 
 
 
 
 
 
 
 
AUCt 
 
 
 
 
 
 
 
AUC(0-0.5hr) 
 
 
 
 
 
 
 
AUC(0-1hr) 
 
 
 
 
 
 
 
AUC(0-2hr) 
 
 
 
 
 
 
 
AUCi 
 
 
 
 
 
 
 
 


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  
 
 
 Confidential         
 
            
 
 
 Page 36 of 82                                                                          
                                                                                                                                                                                                                                                                                                           
 
PARAMETER 
90% 
CONFIDENCE 
INTERVAL 
FOR M207 Arm 
30 (A) and INT 
Spray 2.5 (D) 
90% 
CONFIDENCE 
INTERVAL FOR 
M207 Thigh 30 
(B) and INT 
Spray 2.5 (D) 
90% 
CONFIDENCE 
INTERVAL 
FOR M207 Arm 
60 (C) and INT 
Spray 2.5 (D) 
90% 
CONFIDENCE 
INTERVAL FOR 
M207 Arm 30 (A) 
and M207 Thigh 
30 (B) 
90% 
CONFIDENCE 
INTERVAL 
FOR M207 Arm 
30 (A) and M207 
Arm 60 (C) 
90% 
CONFIDENCE 
INTERVAL 
FOR M207 
Thigh 30 (B) and 
M207 Arm 60 
(C) 
POWER 
TOST  
Cmax 
 
 
 
 
 
 
 
AUCt 
 
 
 
 
 
 
 
AUC(0-0.5hr) 
 
 
 
 
 
 
 
AUC(0-1hr) 
 
 
 
 
 
 
 
AUC(0-2hr) 
 
 
 
 
 
 
 
AUCi 
 
 
 
 
 
 
 
 
Note: All the above provided summary table of statistical analysis will be provided for metabolite n-desmethyl zolmitriptan as a supportive 
information. 


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  
 
 
 Confidential         
 
            
 
 
 Page 37 of 82                                                                          
                                                                                                                                                                                                                                                                                                           
Summary Table 14.3.1.1: Overview of Adverse Event 
 
 
Treatment 
 
Treatment 
(A) 
Treatment 
(B) 
Treatment  
(C) 
Treatment  
(D) 
subjects who received study treatment 
 
 
 
 
subjects who discontinued due to AEs 
 
 
 
 
subjects with at least one AE 
 
 
 
 
Total number of AEs 
 
 
 
 
Total number of SAEs 
 
 
 
 
Source: Appendix 16.2.1 and 16.2.7 
 


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  
 
 
 Confidential         
 
            
 
 
 Page 38 of 82                                                                          
                                                                                                                                                                                                                                                                                                           
Summary Table 14.3.1.2: Incidence of AE by SOC and PT by Treatment Group 
 
 
Treatment 
System Organ Class / 
Preferred Term 
Treatment 
(A) 
(N= XX) 
n (%) 
Treatment 
(B) 
(N= XX) 
n (%) 
Treatment 
(C) 
(N= XX) 
n (%) 
Treatment  
(D) 
(N= XX) 
n (%) 
Number of AEs 
 
 
 
 
Number of subjects with at least one AE 
 
 
 
 
System Organ Class 
 
 
 
 
Preferred Term  
 
 
 
 
 
 
 
 
 
Abbreviations: AE=Adverse Event; SOC=System Organ Class; PT=Preferred Term; 
N=number of subjects dosed for each treatment; n=number of subjects reporting at least one incidence of the specified AE. 
Medical Dictionary used: MedDRA Version XX.X 
 


                                                                                                                                                    
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  Confidential         
 
            Page 39 of 82                                                
 
Summary Table 14.3.1.3: Summary of Treatment Emergent Adverse Events by SOC, PT 
and Severity 
 
System Organ 
Class / 
Preferred 
Term 
Treatment A 
(N=XX) 
n (%) 
Treatment B 
(N=XX) 
n (%) 
Treatment C 
(N=XX) 
n (%) 
Treatment D 
(N=XX) 
n (%) 
Number of 
subjects with at 
least one AE 
XX (XX.XX) 
XX (XX.XX) 
XX (XX.XX) 
XX (XX.XX) 
Mild 
XX (XX.XX) 
 
XX (XX.XX) 
 
XX (XX.XX) 
 
XX (XX.XX) 
 
Moderate 
XX (XX.XX) 
 
XX (XX.XX) 
 
XX (XX.XX) 
 
XX (XX.XX) 
 
Severe 
XX (XX.XX) 
XX (XX.XX) 
XX (XX.XX) 
XX (XX.XX) 
 
 
 
 
 
System Organ 
Class 1  
XX (XX.XX) 
XX (XX.XX) 
XX (XX.XX) 
XX (XX.XX) 
  Preferred     
Term 1 
XX (XX.XX) 
XX (XX.XX) 
XX (XX.XX) 
XX (XX.XX) 
Mild 
XX (XX.XX) 
 
XX (XX.XX) 
 
XX (XX.XX) 
 
XX (XX.XX) 
 
Moderate 
XX (XX.XX) 
 
XX (XX.XX) 
 
XX (XX.XX) 
 
XX (XX.XX) 
 
Severe 
XX (XX.XX) 
XX (XX.XX) 
XX (XX.XX) 
XX (XX.XX) 
 
 
 
 
 
System Organ 
Class 2  
XX (XX.XX) 
XX (XX.XX) 
XX (XX.XX) 
XX (XX.XX) 
Preferred Term 
2  
 
 
 
 
----  
---- 
---- 
---- 
---- 
Abbreviations: N=Number of subjects in specified treatment group; n = number of subjects in specified 
category.  
Notes: 2) A subject is counted only once at the highest severity, in the severity sub-categories. 
Medical Dictionary used: MedDRA Version XX.X  
 


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  Confidential         
 
            Page 40 of 82                                                
                                                                                                                                                                                                                                                                      
Summary Table 14.3.1.4: Summary of Treatment Emergent Adverse Events by SOC, PT 
and Causality 
 
System Organ Class / 
Preferred Term 
Treatment 
A 
(N=XX) 
n (%) 
Treatment 
B 
(N=XX) 
n (%) 
Treatment 
C 
(N=XX) 
n (%) 
Treatment D 
(N=XX) 
n (%) 
Number of subjects 
with at least one AE 
XX 
(XX.XX) 
XX 
(XX.XX) 
XX 
(XX.XX) 
XX (XX.XX) 
        Not Related 
XX 
(XX.XX) 
XX 
(XX.XX) 
XX 
(XX.XX) 
XX (XX.XX) 
       Possibly Related 
XX 
(XX.XX) 
XX 
(XX.XX) 
XX 
(XX.XX) 
XX (XX.XX) 
        Probably Related 
XX 
(XX.XX) 
XX 
(XX.XX) 
XX 
(XX.XX) 
XX (XX.XX) 
System Organ Class 1  
XX 
(XX.XX) 
XX 
(XX.XX) 
XX 
(XX.XX) 
XX (XX.XX) 
Preferred Term 1  
XX 
(XX.XX) 
XX 
(XX.XX) 
XX 
(XX.XX) 
XX (XX.XX) 
        Not Related 
XX 
(XX.XX) 
XX 
(XX.XX) 
XX 
(XX.XX) 
XX (XX.XX) 
       Possibly Related 
XX 
(XX.XX) 
XX 
(XX.XX) 
XX 
(XX.XX) 
XX (XX.XX) 
        Probably Related 
XX 
(XX.XX) 
XX 
(XX.XX) 
XX 
(XX.XX) 
XX (XX.XX) 
Abbreviations: N=Number of subjects in specified treatment group; n = number of subjects in specified 
category. 
Notes: Multiple reports of same TEAE (for Summary Table 9) / SAE (for Summary Table 
10) for the same subject were counted once. 
Medical Dictionary used: MedDRA Version XX.X  


                                                                                                                                                    
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  Confidential         
 
            Page 41 of 82                                                
 
Listing 1: Listing of Adhesion Score for Test Treatment (A) - M207 Arm 30 minutes 
 
Subject 
Sequence 
Pre-Dose 
30 minutes 
XXXX 
 
 
 
XXXX 
 
 
 
XXXX 
 
 
 
  


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  Confidential         
 
            Page 42 of 82                                                
Listing 2: Listing of Adhesion Score for Test Treatment (B) - M207 Thigh 30 minutes 
 
Subject 
Sequence 
Pre-Dose 
30 minutes 
XXXX 
 
 
 
XXXX 
 
 
 
XXXX 
 
 
 
 


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  Confidential         
 
            Page 43 of 82                                                
Listing 3: Listing of Adhesion Score for Test Treatment (C) - M207 Arm 60 minutes 
 
Subject No. 
Sequence 
Pre-Dose 
30 minutes 60 minutes Mean Score 
XXXX 
 
 
 
 
 
XXXX 
 
 
 
 
 
XXXX 
 
 
 
 
 
 


 
 
                                                                                                                               
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  Confidential         
 
            Page 44 of 82                                                
 
Summary Table 14.3.2: Descriptive Statistics by Treatment for Adhesion  
 
Variable 
N 
Mean 
Std Dev 
Minimum 
Maximum 
Median 
Treatment (A) - 
M207 Arm 30 
minutes 
Treatment (B) - 
M207 Thigh 30 
minutes 
Treatment (C) - 
M207 Arm 60 
minutes 
 
 
 
 
 
 
 


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  Confidential         
 
            Page 45 of 82                                                
                                                                                                                                                                                                                                                                      
Summary Table 14.3.4: Descriptive Statistics by Treatment for ECG Parameters  
 
Heart Rate 
Variables 
0 
minutes 
15 
minutes 
60 
minutes 
8 hour 
12 hour 
48 hour 
Treatment (A) 
-  M207 Arm 
30 minutes 
N 
 
 
 
 
 
 
Mean 
 
 
 
 
 
 
Std Dev 
 
 
 
 
 
 
Minimum  
 
 
 
 
 
Maximum  
 
 
 
 
 
Median 
 
 
 
 
 
 
 
Note: Same tables needs to be followed for rest of the treatments and variables i.e. PR 
Interval, QRS Interval, QT Interval and QTcF.  
 


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  Confidential         
 
            Page 46 of 82                                                
                                                                                                                                                                                                                                                                      
Summary Table 14.3.4.1: Descriptive Statistics by Treatment for Vital Signs  
 
Systolic_blood_pressure 
Variables 
0 
minutes 
10 
minutes 
60 
minutes 
2 hour 
4 hour 
12 hour 
48 
hour 
Treatment 
(A) -  M207 
Arm 30 
minutes 
N 
 
 
 
 
 
 
 
Mean 
 
 
 
 
 
 
 
Std Dev  
 
 
 
 
 
 
Minimum  
 
 
 
 
 
 
Maximum  
 
 
 
 
 
 
Median  
 
 
 
 
 
 
 
Note: Same tables needs to be followed for rest of the treatments and variables i.e. 
Diastolic_blood_pressure, Heart_Rate, Respiratory_rate and Body Temprature.  
 


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  Confidential         
 
            Page 47 of 82                                                
                                                                                                                                                                                                                                                                      
Summary Table 14.3.5: Descriptive Statistics by Treatment for Investigator Visual 
Skin Evaluation  
 
Erythema 
Variables 
Pre-dose 
30 
minutes 
60 
minutes 
12 hour 
24 hour 
48 hour 
Treatment 
(A) - M207 
Arm 30 
minutes 
N 
 
 
 
 
 
 
Mean 
 
 
 
 
 
 
Std Dev 
 
 
 
 
 
 
Minimum  
 
 
 
 
 
Maximum  
 
 
 
 
 
Median 
 
 
 
 
 
 
 
Note: Same tables needs to be followed for rest of the treatments and variables i.e. Edema, 
Bruising and Bleeding.  


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  Confidential         
 
            Page 48 of 82                                                
                                                                                                                                                                                                                                                                      
Summary Table 14.3.6: Frequency by Treatment for Investigator Visual Skin 
Evaluation  
 
Frequency_Erythema 
Variables 
Pre-dose 
30 
minutes 
60 
minutes 
12 hour 
24 hour 
48 hour 
Treatment  
(A) - M207 
Arm 30 
minutes 
0 
 
 
 
 
 
 
1 
 
 
 
 
 
 
2 
 
 
 
 
 
 
3 
 
 
 
 
 
 
 
Note: Same tables needs to be followed for rest of the treatments and variables i.e. Edema, 
Bruising and Bleeding.  


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  Confidential         
 
            Page 49 of 82                                                
                                                                                                                                                                                                                                                                      
 Summary Table 14.3.7: Descriptive Statistics by Treatment for Adhesion  
 
Variable 
N 
Mean 
Std Dev 
Minimum 
Maximum 
Median 
Treatment (A) - 
M207 Arm 30 
minutes 
Treatment (B) - 
M207 Thigh 30 
minutes 
Treatment (C) - 
M207 Arm 60 
minutes 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 


 
 
                                                                                                                               
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  Confidential         
 
            Page 50 of 82                                                                                                                                                                           
 
Listing 14.2.1: Time (unit) and Plasma M207 Concentration (unit) Data of Test Treatment-M207 Arm 30 minutes for 
Individual Subjects  
 
  
Time (hrs) 
 0.000 
0.033 
 0.083 
0.167 
0.250 
0.333 
0.500 
0.750 
1.000 
1.500 
2.000 
4.000 
8.000 
12.000 
24.000 
Subject 
Sequence 
Period 
Concentration (unit) 
XXXX 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  
 
 
 Confidential         
 
            
 
 
 Page 51 of 82                                                                          
 
Listing 14.2.2: Time (unit) and Plasma M207 Concentration (unit) Data of Test Treatment-M207 Thigh 30 minutes for Individual Subjects  
 
  
Time (hrs) 
 0.000 
0.033 
 0.083 
0.167 
0.250 
0.333 
0.500 
0.750 
1.000 
1.500 
2.000 
4.000 
8.000 
12.000 
24.000 
Subject 
Sequence 
Period 
Concentration (unit) 
XXXX 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  
 
 
 Confidential         
 
            
 
 
 Page 52 of 82                                                                          
 
Listing 14.2.3: Time (unit) and Plasma M207 Concentration (unit) Data of Test Treatment-M207 Arm 60 minutes for Individual Subjects  
 
  
Time (hrs) 
 0.000 
0.033 
 0.083 
0.167 
0.250 
0.333 
0.500 
0.750 
1.000 
1.500 
2.000 
4.000 
8.000 
12.000 
24.000 
Subject 
Sequence 
Period 
Concentration (unit) 
XXXX 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  
 
 
 Confidential         
 
            
 
 
 Page 53 of 82                                                                          
 
Listing 14.2.4: Time (unit) and Plasma M207 Concentration (unit) Data of Test Treatment-INT Spray 2.5 mg for Individual Subjects  
 
  
Time (hrs) 
 0.000 
0.033 
 0.083 
0.167 
0.250 
0.333 
0.500 
0.750 
1.000 
1.500 
2.000 
4.000 
8.000 
12.000 
24.000 
Subject 
Sequence 
Period 
Concentration (unit) 
XXXX 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  
 
 
 Confidential         
 
            
 
 
 Page 54 of 82                                                                          
 
Listing 14.2.5: Pharmacokinetic Parameter and Ratio Values of zolmitriptan for Individual Subjects  
 
Subject 
Sequence 
Cmax (unit) 
AUCt (unit) 
A 
B 
C 
D 
A/B 
A/C 
A/D 
B/C 
B/D 
C/D 
A 
B 
C 
D 
A/B 
A/C 
A/D 
B/C 
B/D 
C/D 
XXXX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subject 
Sequence 
AUC(0-0.5) (unit) 
AUC(0-1) (unit) 
A 
B 
C 
D 
A/B 
A/C 
A/D 
B/C 
B/D 
C/D 
A 
B 
C 
D 
A/B 
A/C 
A/D 
B/C 
B/D 
C/D 
XXXX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subject 
Sequence 
AUC(0-2) (unit) 
AUCi (unit) 
A 
B 
C 
D 
A/B 
A/C 
A/D 
B/C 
B/D 
C/D 
A 
B 
C 
D 
A/B 
A/C 
A/D 
B/C 
B/D 
C/D 
XXXX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  
 
 
 Confidential         
 
            
 
 
 Page 55 of 82                                                                          
 
Listing 14.2.6: Pharmacokinetic Parameter Values of zolmitriptan for Individual Subjects 
 
Subject 
Sequence 
Tmax 
(unit) 
Kel 
(unit) 
tHalf 
(unit) 
A 
B 
C 
D 
A 
B 
C 
D 
A 
B 
C 
D 
XXXX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subject 
Sequence 
REGSTART (unit) 
REGEND (unit) 
NUMPT 
AUC_%Extrap_obs 
A 
B 
C 
D 
A 
B 
C 
D 
A 
B 
C 
D 
A 
B 
C 
D 
XXXX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: All the above provided summary table of pharmacokinetics will be same presented for metabolite n-desmethyl zolmitriptan as a 
supportive information. All treatments lables will be provided in footenote for this table. 


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  
 
 
 Confidential         
 
            
 
 
 Page 56 of 82                                                                          
 
Listing 14.2.7: Pharmacokinetic Parameter Frel of zolmitriptan for Individual Subjects 
 
Subject 
Sequence 
AUCt 
(unit) 
Frel (%)  
A 
B 
C 
A & B  
A & C 
B & C 
XXXX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Above mentioned table will be same presented for metabolite n-desmethyl zolmitriptan as a supportive information. All treatments lables 
will be provided in footenote for this table. 


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  
 
 
 Confidential         
 
            
 
 
 Page 57 of 82                                                                          
 
Listing 14.2.8: Amount of Residual Drug on Used Test Treatment-A for Individual Subjects at 30 minutes (Upper Arm Application)  
 
  
Time (hrs) 
0.500 
Subject 
Sequence 
Period 
Amount (unit) 
Patch-1 
Patch-2 
XXXX 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  
 
 
 Confidential         
 
            
 
 
 Page 58 of 82                                                                          
 
Listing 14.2.9: Amount of Residual Drug on Used Test Treatment-B for Individual Subjects at 30 minutes (Thigh Application) 
 
  
Time (hrs) 
0.500 
Subject 
Sequence 
Period 
Amount (unit) 
Patch-1 
Patch-2 
XXXX 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  
 
 
 Confidential         
 
            
 
 
 Page 59 of 82                                                                          
 
Listing 14.2.10: Amount of Residual Drug on Used Test Treatment-C for Individual Subjects at 60 minutes (Upper Arm Application) 
 
  
Time (hrs) 
1.000 
Subject 
Sequence 
Period 
Amount (unit) 
Patch-1 
Patch-2 
XXXX 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  
 
 
 Confidential         
 
            
 
 
 Page 60 of 82                                                                          
 
Listing 14.2.11: Amount of Residual Drug on Skin (3 Swabs) after removing Test Treatment-M207 Arm 30 minutes, Test Treatment-M207 Thigh 30 
minutes and Test Treatment-M207 Arm 60 minutes for Individual Subjects  
 
  
Treatment-A 
Treatment-B 
Treatment-C 
Time (hrs) 
Time (hrs) 
Time (hrs) 
0.500 
0.500 
1.000 
Subject 
Sequence 
Period 
Amount (unit) 
Amount (unit) 
Amount (unit) 
XXXX 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 


 
 
                                                                                                                               
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  Confidential         
 
            Page 61 of 82                                                
 
Listing 14.2.12: Listing of Adhesion Score for Test Treatment (A) - M207 Arm 30 
minutes 
 
Subject 
Sequence 
Pre-Dose 
30 minutes 
XXXX 
 
 
 
XXXX 
 
 
 
XXXX 
 
 
 
 


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  Confidential         
 
            Page 62 of 82                                                
 
Listing 14.2.13: Listing of Adhesion Score for Test Treatment (B) - M207 Thigh 30 
minutes 
 
Subject 
Sequence 
Pre-Dose 
30 minutes 
XXXX 
 
 
 
XXXX 
 
 
 
XXXX 
 
 
 


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  Confidential         
 
            Page 63 of 82                                                
 
Listing 14.2.14: Listing of Adhesion Score for Test Treatment (C) - M207 Arm 60 
minutes 
 
Subject No. 
Sequence 
Pre-Dose 
30 minutes 
60 minutes 
Mean Score 
XXXX 
 
 
 
 
 
XXXX 
 
 
 
 
 
XXXX 
 
 
 
 
 


 
 
                                                                                                                               
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  Confidential         
 
            Page 64 of 82                                                                                                                                                                           
 
Listing 14.2.15: PK Blood Sampling Time Deviations  
 
Subject 
Period 
Time Point 
Deviation 
+/- (minutes) 
Actual 
Blood collection time (hr) 
XXXX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  
 
 
 Confidential         
 
            
 
 
 Page 65 of 82                                                                          
 
Listing 16.1.6: Listing of Subjects Receiving Treatment 
 
Subject 
Period 
Treatment 
Dosing Date 
(DDMMMYY) 
Dosing Start Time 
(HH:MM) 
XXXX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  
 
 
 Confidential         
 
            
 
 
 Page 66 of 82                                                                          
 
Listing 16.2.1: Listing of Subject Disposition  
 
Subject  
Period 
Date of 
Completion/Discontinuation 
(DDMMMYYYY) 
Status* 
XXXX 
 
 
 
*If status is OTHER, specify the reason for non-completion.  


 
 
                                                                                                                               
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  Confidential         
 
            Page 67 of 82                                                
 
Listing 16.2.2: Protocol Deviations 
 
Period Subject 
Sample 
Time Point 
(hours) 
#Minutes 
 
Early/Late Deviation 
Impact Assessment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: NA: Not Available 
 


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  Confidential         
 
            Page 68 of 82                                                
 
Listing 16.2.2.1: Other Protocol Deviations 
 
Subject 
Period 
Date of Deviation 
(DDMMMYYYY) 
Deviation 
XXXX 
1 
 
 
 
 
2 
 
 
 
 
 
 
3 
 
 
 
 
4 
 
 
 
 


 
 
                                                                                                                               
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  
 
 
 Confidential         
 
            
 
 
 Page 69 of 82                                                                          
 
Listing 16.2.4: Demographic Data* 
 
Subject 
Collection Date 
(DDMMYYYY) 
Age 
(Years) 
Weight 
(kg) 
Height 
(cm) 
BMI 
(kg/m2) 
Sex 
Race 
Ethnicity 
XXXX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Determined at Screening 
Note:- BMI: Body Mass Index 
 


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  
 
 
 Confidential         
 
            
 
 
 Page 70 of 82                                                                          
 
Listing 16.2.7: Adverse Events Listings 
 
 
ONSET 
END 
 
Subject Drug 
Dosing 
Time 
& 
Date 
Period 
Adverse 
Event 
Adverse 
Event 
(Preferred 
term) 
Date 
(DDMMMYY) 
Time 
(HH:MM) 
Date 
(DDMMMYY) 
Time 
(HH:MM) Severity 
Serious 
Y = 
YES 
N = 
NO 
Relationship 
to drug 
Resolution, 
Other 
Action 
Taken 
Outcome
Caused Study 
Discontinuation
Y = YES 
N = NO 
 
XXXX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical Dictionary used: MedDRA Version XX.X 
 


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  
 
 
 Confidential         
 
            
 
 
 Page 71 of 82                                                                          
 
Listing 16.2.7.1: Listing of Prior and Concomitant Medication 
 
Subject 
Site 
Medication Name 
Or Therapy 
Medication 
given for 
Indication 
Dose Per 
Administration 
& Unit   
Frequency Route 
Start Date 
(DDMMMYYYY) 
End Date 
(DDMMMYYYY) 
P/C 
XXXX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: P/C: P=Prior C=Concomitant. Medications that were stopped prior to first dose of study drug are termed as 'Prior'. 
WHO DD Version: xxxxxxxx. 


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  
 
 
 Confidential         
 
            
 
 
 Page 72 of 82                                                                          
 
Listing 16.2.8: Listing Drug Screen-Alcohol Breath Testing Results at Screening and at Admission/baseline 
 
Subject 
Site 
Collection Date 
(DDMMMYYYY) 
Collection Time 
(HHMM) 
Visit 
Panel Name 
Test  
Result 
XXXX 
 
 
 
 
 
XXXXXXX 
Positive 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  
 
 
 Confidential         
 
            
 
 
 Page 73 of 82                                                                          
 
Listing 16.2.8.1: Listing Abnormal Clinically Significant Lab Results 
 
Subject  
Visit 
Date 
Laboratory Test 
Units 
Range 
Results 
Abnormality 
Flag 
XXXX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  
 
 
 Confidential         
 
            
 
 
 Page 74 of 82                                                                          
 
Listing 16.2.8.2: Listing of Pregnancy Test Results Performed on Screening and Admission/baseline  
 
Subject 
Visit 
Pregnancy test performed? 
Date of test performed 
(DDMMMYYYY) 
Result  
XXXX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  
 
 
 Confidential         
 
            
 
 
 Page 75 of 82                                                                          
 
Listing 16.2.8.3: Listing of Patch Retainment and Residual Drug Collection  
 
Subject 
Treatment 
Patch 
site 
Collection 
Collection Date  
(DDMMMYYYY) 
Collection Time  
(HH:MM) 
XXXX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  
 
 
 Confidential         
 
            
 
 
 Page 76 of 82                                                                          
 
Listing 16.2.8.4: Listing of Vital Signs Assessments 
 
Subject 
Visit 
Vital Signs Date 
(DDMMMYYYY) 
Time  
(HHMM) 
Vital Sign 
(Unit) 
Result 
XXXX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  
 
 
 Confidential         
 
            
 
 
 Page 77 of 82                                                                          
 
Listing 16.2.8.5: Listing of Medical History 
 
Subject 
Site 
Medical 
History 
Category 
Medical / 
Surgical Term 
Start Date 
(DDMMMYYYY) 
Stop Date 
(DDMMMYYYY) 
Ongoing 
XXXX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  
 
 
 Confidential         
 
            
 
 
 Page 78 of 82                                                                          
 
Listing 16.2.8.6: Listing of Physical Examination at Screening and 12 hr 
 
Subject 
Site 
Visit 
Date of Physical 
Examination 
(DDMMMYYYY
) 
Body System 
Result 
Abnormal 
Findings 
Clinically 
significant 
Y = Yes 
N = No 
XXXX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  
 
 
 Confidential         
 
            
 
 
 Page 79 of 82                                                                          
 
Listing 16.2.8.7: Listing of Adhesion Assessment at 30 Minute and 60 Minute 
 
Subject 
Patch 
Adhesion 
Assessment 
Time Point 
Adhesion Assessment 
Date 
(DDMMMYYYY) 
Adhesion 
Assessment 
Time (HH:MM) 
Adhesion 
Assessment 
Score 
Adhesion 
Assessment 
Result 
XXXX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  
 
 
 Confidential         
 
            
 
 
 Page 80 of 82                                                                          
 
Listing 16.2.8.8: Listing of  Investigator Visual Skin Evaluation at Pre-dose, 30 Minute, 60 Minute, 12 hour, 24 hour and EOS/Early Term 
 
Subject 
Patch 
Site 
Visual 
Skin 
Assessment 
Time Point 
Visual Skin 
Assessment Date 
(DDMMMYYYY) 
Visual Skin 
Assessment 
Time (HH:MM) 
 
Visual Skin 
Evaluation 
Visual Skin 
Evaluation 
Score 
 
Visual Skin 
Evaluation 
Result 
XXXX 
 
 
 
 
Erythema 
Evaluation 
 
 
 
 
 
 
 
Edema 
Evaluation 
 
 
 
 
 
 
 
Bruising 
Assessment 
 
 
 
 
 
 
 
Bleeding 
Assessment 
 
 
 
 


   
 
 
 
 
 
 
 
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  
 
 
 Confidential         
 
            
 
 
 Page 81 of 82                                                                          
 
Listing 16.2.8.9: Listing of ECG performed on during Screening, Pre-dose, 15 minutes, 60 minutes, 8 hour, 12 hour and End of Study 
 
Subject 
Date of ECG 
performed 
(DDMMMYYYY) 
Time of ECG 
performed 
(HH:MM) 
ECG Parameters 
(unit) 
Result 
Overall 
Interpretation 
If Abnormal, 
Clinically 
significant? 
If Yes, please 
specify 
XXXX 
 
 
Heart Rate (beats/min) 
 
 
 
 
 
 
 
PR Interval (msec) 
 
 
 
 
 
 
 
QRS Interval (msec) 
 
 
 
 
 
 
 
QT Interval (msec) 
 
 
 
 
 
 
 
QTcF - Fridericia`s 
Correction Formula 
(msec) 
 
 
 
 
 
 


 
 
                                                                                                                               
CP-2018-002 SAP Version: Draft DD MMM YYYY              
 
  Confidential         
 
            Page 82 of 82 
 
Figure 1: Linear Mean Plot of Zolmitriptan Treatments over Time 
 
 
 
Figure 2: Mean Plot of Zolmitriptan Treatments over First 2 Hours